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1.  INTRODUCTION 
1.1  Physiology of the Lung 
 1.1.1 Functional anatomy of the lung 
The primary function of the lung is to provide a sufficiently sized and highly efficient 
area for gas exchange. In addition, the lung also serves as a reservoir for blood, 
moves air to and from the exchange surfaces of the lungs, protects the respiratory 
epithelia from dehydration, temperature changes, or other environmental variations 
and defends the respiratory system and the organism from invasion by pathogens. 
Respiratory diseases frequently interfere with ventilation, blood flow and gas 
exchange and might ultimately lead to respiratory failure and death. 
The respiratory tract consists of the airways that carry air to and from the exchange 
surfaces of the lungs. The conducting airways consist of a series of branching tubes 
that become narrower, shorter and more numerous as they penetrate deeper into 
the lung, eventually reaching the terminal bronchioles which are the smallest airways 
without alveoli. Their function is to lead inspired gas to the gas-exchanging regions 
of the lung. Since they lack alveoli and therefore take no part in gas exchange, the 
conducting airways form the anatomic dead space. The respiratory portion of the 
airways includes the delicate respiratory bronchioles and the alveoli where gas 
exchange occurs; it makes up most of the lung and has a volume of 2 to 3 litres in 
adult humans. 
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The cellular composition of the airways is complex, comprising nearly 50 distinct cell 
types, at least 12 of which are epithelial cells on the surface of the conducting 
airways, respiratory bronchioles and alveoli. 
The lung has two well defined interstitial connective tissue compartments arranged 
in series: the parenchymal interstitium and the loose binding connective tissue 
(peribronchovascular sheaths, interlobular septa and visceral pleura)1. The 
parenchymal interstitium of the alveolar wall makes up about 33% of the total 
interstitial volume. These two compartments have significant anatomical and 
functional differences. For instance, collagen type IV is located mainly in the 
parenchymal compartment, the site where the extensive basement membrane of the 
capillary endothelium and alveolar epithelium are found; whereas the lymphatics are 
confined to the loose-binding connective tissue. The bulk of the lung interstitium is 
occupied by the ground substance and matrix of glycosaminoglycans1, 2 as well as 
several different interstitial cells such as mast cells, plasma cells and occasional 
leukocytes, and fibres such as collagen, elastin and reticulin3. The ground substance 
constitutes a complex group of large polysaccharide molecules whose interactions 
impart a gell-like structure to the interstitium2. Thus the lungs are well designed to 
fulfill their major physiological role of gas exchange, whereby incoming fresh air is 
distributed through the branching airways, and in the terminal respiratory units, the 
mixing of gas occurs largely through molecular diffusion4. Incoming mixed venous 
blood flows through a series of branching arteries into a network of capillaries that 
provide a thin film of blood in close proximity to the gas in the terminal respiratory 
units1. Thus, the matching of inspired air (ventilation) with incoming poorly  
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oxygenated blood  occurs at the level of the gas exchange units of the lung and 
thereafter, oxygenated (arterialized) blood flows through a series of pulmonary veins 
to the left heart for distribution to the tissues of the body1. Although gas exchange is 
nearly perfect in the lungs of healthy individuals, it is often impaired in patients with 
lung diseases because of hypoventilation, ventilation-perfusion mismatch, or right-to-
left shunts5, 6. The lungs are also endowed with an elaborate system of nerves, 
lymphatics and specialized cells that regulate gas exchange, protect the lungs and 
contribute to host defense properties7, 8. 
 
1.2 Interstitial Lung Disease 
Under physiological conditions, the interstitial space of the lung is a delicate and 
almost invisible space between the basement membrane of the alveolar epithelium 
and the alveolar capillary endothelium9  (see Figure1). 
  
  Figure 1: Schematic view of the lung parenchyma that surrounds an alveolar space 
      showing the major cells that line and lie within the putative interstitial space.  
      (Adapted from Murray Nadel, Textbook of Respiratory Medicine, Volume 2) 
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Small numbers of interstitial macrophages, fibroblasts and myofibroblasts reside 
within this potential space. The matrix components of the lung, mainly  
collagen and related macromolecules, as well as noncollageneous proteins such as 
fibronectin and laminin10, 11 make up the other components of the lung interstitium. 
 
Interstitial lung disease (ILD) is a compound phrase for description of more than 100 
entities that are causing diffuse parenchymal lung diseases, characterized by a non-
malignant increase of the cellularity of the alveolar, interstitial and/or vascular 
spaces9. To some extent, these diseases possess similar clinical, radiographic, and 
pathophysiological features12. However, they are are distinct in view of their 
underlying etiology and molecular pathophysiology. Patients complain of dyspnea on 
exertion followed by dyspnea at rest13-15. In many ILDs the underlying trigger is 
unknown but it may, in principle, be due to chronic inflammation (for example, 
sarcoidosis, hypersensitivity pneumonitis), or a direct epithelial injury resulting in 
epithelial apoptosis16. Lung fibrosis then develops in response to chronic 
inflammation or repetitive injury of the distal lung epithelium. Regenerative and 
reparative processes take place at the epithelial and endothelial surfaces, ultimately 
leading to fibroblastic proliferation and excessive collagen deposition, the histologic 
hallmark of ILDs14, 16-18. The term diffuse parenchymal lung disease (DPLD) which is 
thought to more fully replace the term ILD, more accurately describes these entities 
as many DPLDs involve not only the alveolar interstitium but also the small airways 
of the lungs including the alveolar ducts, terminal and respiratory bronchioles, and 
lymphatics along the bronchovascular bundle and interlobular septae9. 
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 1.2.1 Classification of Interstitial Lung Disease 
ILDs may develop in response to a variety of causes, e.g. in the frame of 
collagen/vascular diseases, in response to inorganic (asbestos, silicosis) or organic 
(hypersensitivity pneumonitis) dusts, or following medical interventions, such as 
chemo- or radiotherapy19. In contrast, the cause for the idiopathic interstitial 
pneumonias (IIP), (including non-specific interstitial pneumonia [NSIP] and idiopathic 
pulmonary fibrosis [IPF]), granuloma-forming ILD (sarcoidosis) and some rare forms 
such as eosinophilic pneumonia, pulmonary Langerhans cell histiocytosis and 
lymphangioleiomyomatosis, remains unknown up-to-date19. 
Currently, seven distinct subtypes of idiopathic interstitial pneumonias (IIPs) have 
been proposed by the American Thoracic Society/European Respiratory Society 
(ATS/ERS) as shown in Table 114. 
 
Table 1: ATS/ERS classification of idiopathic interstitial pneumonias 
Acute interstitial pneumonia (AIP) 
Cryptogenic organizing pneumonia (COP) 
Desquamative interstitial pneumonia (DIP) 
Lymphoid interstitial pneumonia (LIP) 
Nonspecific interstitial pneumonia (NSIP) 
Respiratory bronchiolitis-interstitial lung disease (RB-ILD) 
Idiopathic pulmonary fibrosis (IPF) 
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Figure 2: Schematic representation of the major categories of interstitial lung 
diseases (ILD), showing the overlap among various disorders.  
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 1.2.2  Prevalence of Interstitial Lung Disease 
The prevalence and incidence of ILDs is often under-estimated: up to 750,000 
patients may suffer from ILDs in the Western World20, and almost 80% of these 
patients are diagnosed with sarcoidosis, idiopathic pulmonary fibrosis (IPF)/non-
specific interstitial pneumonia (NSIP), or hypersensitivity pneumonia. In this regard, 
ILDs are less frequent than asthma, but more patients die from ILDs than from 
asthma each year, illustrating the severity of these diseases20. Although some forms 
of ILD show a generally favorable course (sarcoidosis, early hypersensitivity 
pneumonitis in case of strict antigen removal), others present with poor prognosis 
and may even exhibit a rapidly fatal progressive disease course. IPF, which alone 
may affect up to 150,000 patients in the European Community20, 21  is characterized 
by an average survival time of 3-5 years upon diagnosis14 and represents the most 
aggressive form of ILD.  
 
1.3 Idiopathic Pulmonary Fibrosis (IPF) 
Idiopathic pulmonary fibrosis (or cryptogenic fibrosing alveolitis) [IPF or CFA]  
is a distinct type of idiopathic interstitial pneumonia of yet unknown etiology limited to 
the lungs and associated with a surgical lung biopsy showing a histological pattern 
of usual interstitial pneumonia (UIP)13. IPF is a severe and progressive disease19, 22   
and it is relatively rare. Although the exact prevalence is not known, a prevalence 
rate of 3 to 6 cases per 10,000 population is estimated15. 
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IPF is more frequently diagnosed in men than women, (male: female prevalence 
ratio of 1.4:1 and a male: female incidence ratio of 1.3:1). Although there is a wide 
range in the age of IPF patients (35 to 70 years), a majority of patients are over 60 
years old. In addition, cases of IPF have been reported in young children and 
infants13, 14.  Following diagnosis, the mean survival time is 3.2 to 5 years18, 19, 23.  
 
 1.3.1 Clinical and histological features of IPF 
Patients with IPF typically complain of a dry, nonproductive cough and dyspnea for 
at least 3 to 4 months13, 14.  Dyspnea is often associated with exertion early in the 
disease course, but usually progresses to shortness of breath at rest18. Physical 
exercise is progressively diminished and impossible in later stages, even with long-
term oxygen treatment13, 14. On physical examination, 25% - 50% of patients have 
evidence of clubbing and bi-basilar, end-expiratory rales are observed  in greater 
than 80% of patients15.  Late in the course of the disease, cyanosis of the lips and 
fingers as well as signs of pulmonary hypertension may be seen24. Recurrent 
respiratory infections, in part due to a compromised pulmonary innate immune 
defense, are a frequent observation and fuel further aggravation of this disease 
(Guenther,A., personal communication). Faced with an ever diminishing quality of 
life, the only option for IPF patients is lung transplantation, the long-term outcome 
being largely limited by fibroproliferation as a result of chronic rejection processes 
(bronchiolitis obliterans)25-27.  IPF thus represents a prototypic ILD with a disastrous 
outcome.  
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Specific laboratory tests for the diagnosis of UIP are not available. A restrictive 
pattern is the classic finding on pulmonary function testing in IPF28. Greater than 
90% of patients with UIP will have abnormal chest radiographs at the time of 
diagnosis manifesting the characteristic pattern of diffuse bilateral interstitial or 
reticulonodular infiltrates in the basilar and subpleural regions of the lung 15, 18.  
Employing high-resolution computed tomography (HRCT) in IPF reveals coarse 
reticular or linear opacities (intralobular and interlobular septal thickening) commonly 
found in the periphery and lower lobes of the lungs, honeycomb cysts, and traction 
bronchiectasis29. Ground glass opacities (ill-defined hazy zones representing active 
alveolitis or fibrosis of the intralobular and alveolar septae) may be locally present or 
completely absent 29-31. Extensive honeycombing, septal thickening, and a lack of 
ground glass opacities reflect a poor prognosis18.  
 
A surgical lung biopsy showing a UIP pattern increases the diagnostic certainty of 
IPF18. Video-assisted thoracoscopic surgical (VATS) biopsy is the preferred method 
of obtaining lung tissue and is generally safe32, 33. 
 
 1.3.2 Diagnosis of IPF 
IPF is diagnosed on the basis of clinical, histological and radiological findings13-15. 
Usual interstitial pneumonia (UIP) is the typical histological pattern that characterizes 
patients with the clinical disease called IPF12-14, 34. UIP is characterized by temporal 
and spatial heterogeneity and the presence of fibroblast foci. These changes are 
readily seen with low power microscopy, with areas of normal appearing lung tissue 
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alternating with areas of peripheral fibrosis, inflammatory cells and distortion of the 
normal lung architecture resulting  in the  formation honeycomb cysts and fibroblast 
foci14, 34, 35.  Honeycomb cysts are enlarged and distorted airspaces, lined by 
hyperplastic alveolar type II cells, resulting from destruction of the normal alveoli18. 
Fibroblast foci are areas with aggregates of fibroblasts/myofibroblasts and 
connective tissue located just beneath hyperplastic type II pneumocytes and found 
at the border between fibrotic and normal lung. The distribution of pathological 
changes is subpleural, paraseptal and prominent at the bases14. A UIP pattern may 
also be seen in other conditions apart from IPF such as Hermansky-Pudlack 
syndrome (HPS), hypersensitivity pneumonitis or asbestos-induced lung fibrosis. 
 
 1.3.3 The initial trigger of IPF 
The alveolar epithelial type II (AECII) cell is thought to be at the center of a 
pathomechanistic concept for sporadic or familial IPF, and also for other ILDs, such 
as the Hermansky Pudlack Syndrome (HPS), amiodarone-induced pneumonitis, or 
irradiation-induced lung fibrosis16, 36. Both enhanced AECII cell apoptosis and 
hyperplasia have been reported in IPF specimen, ultimately inducing distorted 
epithelial-mesenchymal cross-talk, resulting in enhanced fibroblast activation and 
ECM synthesis. Ultrastructural studies have revealed the existence of proliferative 
alveolar epithelial cells immediately adjacent to injured epithelial cells37-39, 
suggesting that epithelial apoptosis and proliferation and hyperplasia occur 
simultaneously during the process of fibrosis. According to this concept, chronic 
endoplasmic reticulum (ER) or lysosomal stress have been reported to induce AECII 
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cell apoptosis and thus set the stage for the development of lung fibrosis37-39. In 
detail, mutations in the SFTPC {Surfactant Protein (SP)-C}40 and the TR/TERT 
(telomerase)41 genes in familial forms of idiopathic interstitial pneumonias (mostly 
IPF and NSIP) provided initial evidence that ER-stress-induced apoptosis of AECII 
cells may represent an important pathogenetic trigger event40. Furthermore, 
activation of ER stress pathway components including endoplasmic reticulum to 
nucleus signaling 1 (ERN1) (by proof of X-box binding protein (XBP) 1 splicing) and 
activating transcription factor 6 (ATF6) was observed in sporadic IPF and NSIP, and 
found to result in a persistent and overwhelming ER stress response and induction 
of epithelial apoptosis via DNA-damage-inducible transcript 3 (DDIT3)42. Drawn 
against this background it seems noteworthy that respiratory infections represent a 
common phenomenon in IPF43. These respiratory infections frequently antecede the 
clinical appearance of the disease and also  accelerate the clinical course. 
Consistent with these observations, bacterial44, and – even more compelling – viral45 
infections can induce severe ER-stress. Thus, an intriguing and unifying concept for 
sporadic and familial IPF would consist of a genetic predisposition to an epithelial 
injury, a modifying environmental stimulus and a common downstream pathway 
resulting in fibrosis based on ER stress (or DNA damage) induced AECII cell 
apoptosis. Other diseases resulting in chronic AECII cell injury, such as HPS, 
amiodarone- or irradiation-induced lung fibrosis, might similarly result in epithelial 
apoptosis and subsequent fibrosis46, and could thus be integrated into this concept. 
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 1.3.4 Mediators of distorted epithelial-mesenchymal interactions in 
lung fibrosis 
Balanced epithelial-mesenchymal interactions are of the utmost importance for 
proper lung development, in particular for regular definition of a proximal-distal axis 
and dichotomous branching47. In the adult lung, mesenchymal-epithelial interactions 
warrant proper lung function and are a prerequisite for the maintenance of the 
trophic alveolar unit, but impaired epithelial-mesenchymal crosstalk between AECII 
cells and subepithelial fibroblasts, as well as dysregulated precursor cell recruitment, 
have recently been shown to contribute to the pathobiology of IPF17, 48. It has been 
proposed that the AECII, by action of cyclooxygenase 2, releases PGE2, which then 
binds to the EP-2 receptor on fibroblasts, increases cAMP levels in the fibroblast and 
thereby inhibits the proliferation and transactivation of this cell 49. In addition, several 
growth factors are released by the AECII cell that control the fibroblast phenotype, 
such as members of the Wnt, BMP, or TGF-β superfamilies50.  In particular, 
enhanced secretion and/or activity of Wnt and TGF-β superfamily members have 
been documented in IPF9, 51. The fibroblast itself is a rich source of FGF-7, FGF-10, 
and HGF. HGF will be released by fibroblasts in dependency of cAMP levels and 
must be activated by extracellular serine proteases such as the HGF activator. FGF-
7, FGF-10, as well as HGF are known to exert a marked influence on AECII cell 
proliferation, migration and survival52 and at least HGF has been shown to be 
released to a much weaker extent from IPF fibroblasts as compared to fibroblasts 
from healthy lungs52.Thus, loss of regenerative capacity of the resident AECII cell 
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population due to loss of FGF-7, FGF-10, or HGF may contribute to the 
pathogenesis of IPF.  
 
 1.3.5 Origin of activated (myo-)fibroblasts in IPF 
While the initial injury in IPF is most likely affecting the AECII cell (see above), it is 
well accepted that the interstitial fibroblast/activated myofibroblast represents the 
key effector cell responsible for the increased ECM deposition that is characteristic 
for this disease16, 36. Fibroblast foci represent the hallmark lesions of IPF, as they 
constitute aggregates of activated myofibroblasts, which promote excessive ECM 
deposition23. The occurrence of fibroblast foci represents an important prognostic 
factor, since their numbers have been correlated with survival in IPF53. Fibroblast 
foci occur in subepithelial layers, close to areas of alveolar epithelial cell injury and 
repair. The number of smooth-muscle-actin-positive, activated (myo)fibroblasts is 
significantly increased in multiple forms of pulmonary fibrosis including IPF, but their 
origin remains to be elucidated. Currently, three major theories attempt to explain 
this hallmark of maladaptive cell activation. It has been demonstrated that resident 
pulmonary fibroblasts proliferate in response to fibrogenic cytokines and growth 
factors, thereby increasing the local fibroblast pool via local fibroproliferation54, 55. In 
addition, several recent studies have shown that bone marrow-derived circulating 
fibrocytes traffic to the lung during experimental lung fibrosis, and serve as 
progenitors for interstitial fibroblasts56. In particular, collagen I-positive fibrocytes 
have been shown to traffic to injured lungs in a chemokine-dependent fashion, 
integrate into the lung ECM, and contribute to enhanced collagen synthesis in 
fibrosis56-58. Third, it was recently proposed that AECII cells are capable of 
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undergoing the process of epithelial-to-mesenchymal transition (EMT), the 
phenotypic, reversible switching of epithelial to fibroblast-like cells, which is initiated 
by an alteration of the transcriptional and proteomic profile of AECII cells59, 60. EMT 
is a highly controlled process initially discovered and described in embryonic 
development and morphogenesis59. The orchestrated series of events initiating EMT 
include remodeling of epithelial cell-cell and cell-matrix adhesion contacts, 
reorganization of the actin cytoskeleton, and induction of mesenchymal gene 
expression. EMT has gained wide recognition as a mechanism that facilitates cancer 
progression and metastasis, as well as the development of chronic degenerative 
fibrotic disorders of the kidney, liver, and lung61-64. Transforming growth factor beta 
(TGF-β) is a main inducer and regulator of EMT in multiple organ systems65. 
 
 1.3.6 Major signaling pathways underlying matrix remodeling in the 
lung 
 
As part of a primary wound healing response, activation of the coagulation cascade 
and suppression of the fibrinolysis system has been observed in patients with IPF 66, 
67, and the cellular origin of these coagulation factors (alveolar macrophages and 
alveolar type II cells) was recently shown68. Analysis of bronchoalveolar lavage fluids 
(BALF) revealed substantial activation of the extrinsic coagulation pathway (tissue 
factor[TF]; FVII), alongside with pronounced suppression of antithrombotic (activated 
protein C) or fibrinolytic (Plasminogen Activator Inhibitor [PAI]-1) activities66, 69. 
These changes promote alveolar and interstitial fibrin deposition, forming a 
provisional matrix and thereby substantially contributing to lung fibrosis70. Moreover, 
several procoagulant serine proteases such as TF/FVII, factor X and thrombin 
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induce fibrotic events via the Protease activated receptor (PAR)-1 and PAR-271. In 
response to the activation of this G-protein coupled receptor, increased ECM 
production and secretion and induction of profibrotic growth factors such as TGF-ß 
and PDGF can be observed71. Vice versa, the urokinase system has repeatedly 
been shown to exert strong antifibrotic activity, most likely due to the activation of 
HGF and the removal of fibrin and ECM72. Persistent suppression of urokinase by 
PAI-1 overexpression, as seen in IPF patients and in animal models of lung fibrosis, 
would thus contribute to the development of lung fibrosis72, 73.  Alveolar deposition or 
overexpression of urokinase, knock out of PAI-1 or inhibition of the procoagulant 
pathways by heparin, factor Xa antagonists, direct thrombin inhibitors or activated 
protein C were shown to result in a substantial suppression of the fibrotic response 
in the bleomycin model of lung fibrosis, whereas knock out of urokinase or alveolar 
PAI-1 overexpression induced the opposite effect73, 74.  
 
With respect to scar formation as aberrant alveolar/interstitial wound healing 
response, there is currently no doubt that the TGF-β family represents the pivotal 
mediator system75-78. In vitro, TGF-β induces fibroblast chemotaxis, proliferation 
and transdifferentiation into myofibroblasts, and it largely promotes the production 
and secretion of extracellular matrix compounds, mainly collagen. Application of 
TGF-β encoding adenoviral vectors to the distal lung induces a progressive and 
severe lung fibrosis79. Likewise, application of these vectors to the pleural space 
induces pleural fibrosis and subpleural lung fibrosis as seen in IPF. Increased TGF-
β signaling is also observed in other animal models of lung fibrosis, such as the 
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bleomycin model, where collagen deposition is reduced by TGF-β antibodies and 
soluble TGF-β receptors80. In lungs of IPF patients, increased expression of TGF-β 
has been observed in close proximity to areas of increased ECM deposition81. Apart 
from TGF-β, there are also other growth factors such as PDGF (platelet-derived 
growth factor), CTGF (connective tissue growth factor), members of the Wnt 
pathway, or IGF-I (insulin-like growth factor I) and endothelin, which may 
significantly contribute to the pathogenetic sequelae of IPF75. 
 
Apart from the proliferation of fibroblasts, the excessive deposition of matrix is a key 
feature of IPF and, most likely, is the result of excessive production of ECM 
compounds and a local imbalance between the matrix metalloproteinases (MMP) 
and their inhibitors (TIMP). In general, increased  expression of TIMPs -1, -2 -3 and -
4 and virtual absence of the collagen I specific MMP-1 has been observed in the 
lungs of IPF patients82, thus contributing to collagen deposition. In view of the 
coexistence of fibrotic scars and honeycomb cysts in the lungs of IPF subjects, it is 
yet not settled, if a spatial disarrangement of the collagenases (largely MMP-1) and 
the TIMPs may be the primary reason for the development of this structural 
heterogeneity82, 83. In contrast, the two gelatinases MMP 2 and 9, known for their 
ability to destruct the basement membrane and thus to impair epithelial 
regeneration, were found to be increased in lung fibrosis84. Matrilysin (MMP-7) was 
also found to be highly upregulated in IPF85, 86 and NSIP85 by oligonucleotide 
microarray analysis and immunohistochemistry87. In addition, MMP-7 knock out mice 
were protected from the bleomycin induced lung fibrosis86 thus suggesting that 
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MMP-7 is a  key regulatory molecule in the pathogenesis of IPF and that it  may 
directly or indirectly actively participate in pulmonary fibroproliferation88 . In contrast, 
MMP-9 KO mice showed decreased alveolar bronchiolization after bleomycin-
induced lung fibrosis89 and MMP-12 KO mice were not protected from bleomycin-
induced lung fibrosis90. Taking these together, underscores  the important 
contribution of single MMPs in the dynamic regulation of the ECM and of remodeling 
processes in  the lung91. 
 
 
 1.3.7 Influence of genetic background in IPF pathogenesis 
Familial forms of IPF occur in approximately 10-20% of all IPF cases and are 
characterized by variable penetrance41, 92, 93. The following gene mutations have 
been disclosed. 
 1.3.7.1  Surfactant Protein C mutations 
Two families carrying separate mutations in the surfactant protein (SP)-C gene were 
reported with progressive pneumonitis and lung fibrosis40. SP-C is hydrophobic 
protein and a normal component of alveolar surfactant. It is synthesized in a proform 
requiring C-terminal proteolytic processing for proper folding, assembly with lipid, 
and secretion40, 94, 95. Childhood onset of interstitial pneumonitis and pulmonary 
fibrosis was reported in a family carrying an SP-C mutation40, 41, 92, 96. The mutation 
results in a truncated form of SP-C that accumulates in the endoplasmic reticulum of 
type II alveolar epithelial cells40, 96. A mutation, L188N, in the C-terminal SPC region 
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was found in some family members affected with disease, and also in two unaffected 
obligate heterozygote family members97. Expression of the mutant SP-C protein in 
murine alveolar cells resulted in accumulation of proSP-C and cell toxicity, 
suggesting that misfolded SP-C, through induction of ER stress, may cause AECII 
cell apoptosis and lung fibrosis97.  
1.3.7.2 Telomerase mutation 
Telomerase, a specialized polymerase that adds telomere repeats to the ends of 
chromosomes has two essential constituents: telomerase reverse transcriptase 
(hTERT) required for catalysis and an RNA component called hTR98, 99. Dyskeratosis 
congenita is a rare hereditary disorder initially described on the basis of a triad of 
mucocutaneous manifestations: skin hyperpigmentation, oral leukoplakia, and nail 
dystrophy100. Twenty percent of patients manifest with pulmonary fibrosis, which is 
the second most common cause of death41. Armanios and colleagues recently 
reported a pedigree with autosomal dominant dyskeratosis congenita that carried a 
null hTERT allele. Idiopathic pulmonary fibrosis was the only manifestation of 
disease in a patient with a carrier mutation100. The presence of pulmonary fibrosis in 
dyskeratosis congenita, along with the presence of telomerase mutations in some 
families with IPF41, suggests that the fibrotic lesion in patients with short telomeres is 
provoked by a loss of alveolar cells41. Therefore, damage of epithelial cells leads to a 
remodeling response that manifests as UIP/IPF. 
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 1.3.8  Treatment of lung fibrosis- translational approaches 
In striking contrast to the field of PAH, a disease previously characterized by a 
similarly poor outcome, the therapeutic approach to patients with IPF has not 
changed dramatically over the last 10 years101, 102. Apart from standard care, 
including long-term oxygen treatment, aggressive and early treatment of respiratory 
infections, and early listing for lung transplantation if suitable, all recently finished 
phase II/III trials exhibited unsatisfactory results18, 102. Interferon-γ was definitely 
proven to be ineffective in IPF, Pirfenidone (targeting the TGF-β pathway), as well 
as bosentan (targeting the endothelin pathway), have provided initial hope, but failed 
to significantly affect primary study endpoints102, 103. The only larger trial in IPF with a 
significant improvement in the primary study endpoint, albeit with a high drop out 
rate (1/3 of all patients), was the IFIGENIA trial, in which n-acetyl cysteine was 
tested against placebo and was found out to attenuate the loss of lung function102. In 
the meantime, an encouraging increase in clinical trials in the field of IPF can be 
observed. Most of these studies are addressing secondary processes forwarding 
fibrosis per se. An overview is given in figure 3 outlined below. 
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 Figure 3: Overview of some of the key pathogenetic mechanisms and new 
  treatment modalities in UIP/IPF.  




1.4 Animal models of IPF 
In order to study the evolution of human pulmonary fibrosis and the cellular and 
other profibrotic mediators involved in the disease several animal models have been 
developed. In a recent review, Moore and Hagaboam104 have extensively discussed 
the characteristics, advantages and disadvantages of these animal models as 
summarized in Table 2. 
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Table 2: Advantages and disadvantages of various animal models of fibrosis104 
Model     Advantages     Disadvantages 
 
Bleomycin 
• Most well-characterized 
• Can be delivered intratracheally, 
   intravenously, intraperitoneally 
   or intranasally 
• Clinically relevant 
• Time frame for development of 
   fibrosis is 24-28days 
 
• Fibrosis is reported to be self- 
   limiting after 28days in the 
   intratracheal model 
• Development of fibrosis is   




• Ability to visualize areas of lung 
    injury by characteristic green 
    fluorescence 
• Time frame for development of  
   fibrosis is 14-28days 
•  Fibrotic response persists for at 
   least 6 months 
•  Used in C57Bl/6 and Balb/c 
    mice 
•  Persistent nature of fibrotic 
   response makes it amenable to    
   studying viral exacerbations of   
   fibrosis post-FITC  
• Response can vary 
    depending on the lot of FITC 
 
• Solution must be fresh each  
   day and vortexed before   
   each injection 
 
• Model is not clinically  
   relevant 
 
Irradiation 
• Clinically relevant 
 
•   C57Bl/6 mice are iradiation- 
    fibrosis prone 
• Fibrosis can take more than  
   30weeks to develop 
• Expensive per diem costs 
• C3H/HeJ and CBA/J mice  
   are irradiation-fibrosis 
   resistant 
 
Silica 
• Fibrotic nodules resemble those 
   seen in humans exposed to 
   occupational dusts and  
   particulates 
•  Persistent fibrotic stimulus 
• Fibrosis can take 12- 
   16 weeks  to develop 
• Balb/c mice are resistant 
• Special instrumentation is  
   needed if delivered via  
   aerosol 
 
Transgenic 
•  Can study the overexpression of a 
   particular molecule 
 
• Can be expressed under  
   inducible promoters, which allows 
   expression only in adult mice 
•   Compensations can occur in  
    mice that constitutively   
    express  a transgene   
     throughout development 
•   Amount of product produced  
    may not be physiological 
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Viral vectors 
• Can be used to deliver fibrotic or  
   antifibrotic mediators 
 
• Lentivirus vectors can infect many 
    cell types 
•   Immune response may  
     prevent repeated dosing with 
    adenoviral vectors 
 
• Adenoviral vectors have  
    tropism only for epithelial   








• Can study fibroblast from various 
    human fibrotic diseases 
• Expense of immunodificient  
    mice required for adoptive  




    
 
1.5  Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) belong to the family of zinc-containing 
endopeptidases collectively assigned to the “MB clan” of metalloproteinases and the 
metzincin superfamily105-108. The metzincin superfamily comprises enzymes with 
similar metalloproteinases domains; this superfamily is further subdivided into four 
multigene families: astacins, seralysins, ADAMs/ADAM-TS, and MMPs 109, 110. 
The metzincins are distinguished by the so-called metzincin fold and a highly 
conserved motif (HEXXHXXGXXH) containing three histidines, and a conserved 
“methionine turn” (XXMXP) that sits beneath the active site. The third histidine is 
bound to a zinc atom at the catalytic site110-112. 
 
The founding MMP family member was interstitial collagenase (MMP-1), first 
discovered in 1961 by Gross and Lapière in the tail skin of a tadpole (Xenopus) 
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undergoing metamorphosis113. The most recent member, epilysin (MMP-28) was 
reported separately by the groups of Parks and Stronginin in 2001114, 115.  
Currently, 26 related but distinct vertebrate MMPs are known, of which 24 are found 
in mammals116. They have both a descriptive name generally based on a preferred 
substrate and a MMP numbering system based on order of discovery107, 116, 117  
(Table 3). MMPs were initially characterized by their extensive ability to degrade 
extracellular matrix proteins including aggrecan, collagens, elastin, enactin, 
fibronectin, gelatin, laminin, proteoglycans, tenascin, and vitronectin107. More 
recently, it has been recognized that MMPs cleave many other types of peptides and 
proteins and have many other important functions that may be independent of 
proteolytic activity106, 109, 116. There is, however, little consensus about the grouping 
of MMPs and different authorities in the field classify MMPs based on their structural 
similarities, substrate specificity or tissue expression118, 119. One clear division is 
between secreted MMPs and those attached to the cell surface by the intrinsic 
motifs: a transmembrane (TM) domain, a glycosylphosphatidylinositol (GPI) anchor 
or an amino terminal signal anchor (SA)116, 120. Based on their substrate specificity, 
sequence similarity and domain organization, vertebrate MMPs are divided into six 
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Collagens I, II, III, VII, X, XI; aggrecan, α2-macroglobulin,  
C1q, casein,gelatin, fibronectin, myelin basic protein, link 
protein, SPARC, vitronectin, laminin, entactin, versican; 
autolytic, proMMP-1, proMMP-2, proMMP-9 
Collagens I, II, III; aggrecan,  α2-macroglobulin, C1q, 
casein,gelatin, fibrinogen; autolytic, angiotensin I & II, 
bradykinin, plasmin C1 inhibitor 
 
Collagens I, II, III, IV,VII,IX, X, XIV; aggrecan,α2-
macroglobulin, C1q, casein, collagen telopeptides, 
gelatin, fibronectin, perlecan, large tenascin-C; autolytic, 
proMMP-9 
 











































Denatured collagens (gelatin), collagens I, II, III, IV, V, 
VII, X, XI; aggrecan, decorin, elastin, entactin, fibronectin, 
laminin, myelin basic protein, link protein, SPARC, 
tenascin, vitronectin ; autolytic, α2-macroglobulin, 
proTNFα, latent TGFβ, MCP-3, FGFR1, IGFBP-3, IL1-β1, 




Denatured collagens (gelatin), collagens IV, V, XI, XIV; 
aggrecan casein, decorin, elastin, laminin, myelin basic 
protein, link protein, SPARC, vitronectin ; autolytic,  
α2-macroglobulin, angiotensin I & II, IL1-β1, IL-2Rα, 











































Collagens III, IV, V, VII,IX, X, XI; aggrecan, casein, 
collagen telopeptides, decorin, gelatin, elastin, entactin, 
fibrin, fibrinogen, fibronectin, fibulin, laminin, myelin basic 
protein, link protein, perlecan, SPARC, tenascin, 
versican; autolytic, α2-macroglobulin, E-cadherin, 
proTNFα, IGFBP-3, IL1-β1, osteopontin, plasminogen, u-
PA138, PAI-1139, proMMP-1, -3, -7, -8, -9, -13. 
 
 
Collagens III, IV, V; aggrecan, casein, gelatin, elastin, 
fibronectin, link protein; autolytic, proMMP-1, -7, -8, -9 
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Collagen IV, casein, gelatin, fibronectin, laminin; IGBFP-






























Collagens I, IV; aggrecan, casein, decorin, gelatin, 
elastin, fibronectin,  fibulin, laminin, link protein, myelin 
basic protein, SPARC, tenascin, versican; autolytic, α2-
macroglobulin, osteopontin, plasminogen,  proMMP-1, -2, 
-7, -9 
 















































































Collagen I, II, III; aggrecan, gelatin, entactin, fibronectin, 
laminin, perlecan, vitronectin; α2-macroglobulin, factor 
XII, fibrin, fibrinogen proTNFα, proMMP-2, proMMP-13 
 
Aggrecan, fibronectin, entactin, laminin, perlecan, 
proTNFα, proMMP-2 
 
Collagen III, casein, gelatin, fibronectin, laminin, 
victronectin; α2-macroglobulin, proMMP-2 
 






Fibrin, fibrinogen, gelatin, proTNFα140, 141 
 
 
Collagen IV, gelatin, chondroitin and dermatan sulphate 
















































Collagen I, IV, V; aggrecan, gelatin, fibronectin, elastin, 
entactin, laminin, myelin basic protein, osteonectin, 




Collagen IV, aggrecan, COMP, fibronectin, gelatin, 




Aggrecan, amelogenenin, COMP; autolysis 
 
 
INTRODUCTION            1.5.1 Structure and function of MMPs  
 
































Aggrecan, casein, gelatin 
 
 
Gelatin, casein, fibronectin 
 
 




ColA and ColB = Collagenase-like proteins A and B, respectively, are probably the 
murine homologues of MMP-1, COMP = cartilage oligomeric matrix protein, GPI = 
glycosylphosphatidylinositol, SPARC = secreted protein acidic and rich in cysteine. 
  
 1.5.1  Structure and Function of MMPs 
Each MMP consists of a specific domain sequence with several domain motifs. 
MMPs are active at neutral pH and are generally secreted as the inactive proenzyme 
in the extracellular space or anchored to the plasma membrane142. 
Consequently, they generally consist of a signal peptide, a propeptide domain, a 
catalytic domain, hinge region and a C-terminal hemopexin-like domain (Figure 4)116. 
The hinge region and hemopexin-like domain are absent in MMP-7 and -26, the so-
called minimal domain MMPs116, 118. In addition, more complex MMPs possess other 
features such as fibronectin-like repeats, a collagen type V-like domain, furin 
cleavage site, vitronectin inserts or cysteine array motif116, 118. These are discussed 
in more detail in the following sections. 
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 Figure 4: Domain structure of the mammalian MMP family. 
Nine MMPs, including all of the cell membrane-anchored enzymes have a furin 
cleavage domain. C5, collagen-type-V-like domain; Col, collagenase-like protein; 
Cs, cytosolic; Cys, cysteine array; Fn, fibronectin repeat; Fr, furin-cleavage site; 
Pro, propeptide domain; SH, sulfurhydryl (thiol) group; SP, signal peptide; Zn, 
zinc (Adapted and modified from Parks, W.C., Wilson, C.L. and López-Boado, 
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 1.5.1.1 Propeptide domain 
  
The propeptide (pro-) domain of a typical MMP contains approximately 80 amino 
acids with a hydrophobic residue at the amino terminus. It also contains the 
consensus sequence PRCG(V/N)PD, where the thiol group of the cysteine residue 
at position 73  (the “cysteine switch”) ligates with the zinc ion that is held by the 
histidine residues in the catalytic domain of the MMP142. The structure of the 
propeptide domain of MMP-2, MMP-3 and MMP-9 is known to consist of three α-
helices and connecting loops120. A peptide region after the third helix extends to the 
substrate-binding cleft of the catalytic domain (of MMPs) that contains a conserved 
cysteine, which forms a 4th ligand to an active site zinc ion.  In this conformation, the 
enzyme is stable and inactive and is known as a zymogen143, 144. The exception is 
MMP- 23, where the crucial cysteine residue is found in a distinct amino-acid 
sequence128, 145. In addition MMP-11 146, MT-MMPs 147, MMP-21, MMP-23 128 and 
MMP-28 114 have a pro-protein processing sequence RX(K/R)R (where X denotes 
any amino acid), at the C-terminal end of the prodomain106 which is a target 
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 1.5.1.2 Catalytic domain 
The catalytic domain of MMPs contains approximately 160 -170 amino acid 
residues, including the binding motifs for three structural calcium (Ca2+) ions, one 
structural zinc (Zn2+) and one catalytic Zn2+ (hence the prefix “metallo”) in the active 
site, which are required for the stability and the expression of enzymatic activity142. 
The 50 - 54 residues at the C- terminus of the catalytic domain include a highly 
conserved HEXXHXXGXXH sequence (where X denotes any amino acid)111, 116. The 
three histidines coordinate the active site Zn2+. On the carboxy side of the zinc active 
site, MMPs have a conserved methionine residue which is part of a 1,4 - β-turn or 
“Met-turn” that loops the polypeptide chain beneath the catalytic Zn2+ and forms a 
hydrophobic base for the Zn2+-binding site. A water molecule is the fourth ligand of 
the catalytic Zn2+118, 144, 148. The carboxyl group of the glutamate residue (E) [which is 
adjacent to the first histidine] serves as a general base and facilitates the 
nucleophilic attack of the water molecule on the carbonyl carbon of the peptide 
scissile bond120 and histidine residues that coordinate the Zn2+. The side chain of a 
substrate docks into a pocket to the right of the active site Zn2+ known as the 
specificity or S1’ pocket142. The size of the S1’ pocket, one major determinant of 
substrate specificity, varies among the MMPs142. Structurally, the catalytic domain 
consists of a 5-stranded β-pleated sheet, three α-helices and bridging loops111, 142. 
These backbone structures including the Met turn are similar to those of the 
members from other metalloproteinases families: the astacins, reprolysins (ADAMs) 
and serralysins111. In addition, MMP-2 and MMP-9 have 3 repeats of fibronectin-type 
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II domain inserted in the catalytic domain that interact with collagens and gelatins149, 
150. 
 1.5.1.3 Hinge region, hemopexin domain  and other domains 
With the exception of MMP7, -23 and -26, MMPs have a flexible proline-rich hinge 
and a C-terminal hemopexin-like domain, which functions in proper substrate 
recognition, activation of the enzyme, protease localization, internalization 
anddegradation151, 152.  Structurally, the hemopexin domain encodes a 4- bladed β-
propeller structure that is known to mediate protein-protein interactions153.  
 
Other domains found in MMPs are restricted to subgroups of enzymes118. For 
example, the four membrane type (MT)-MMPs (MMP14, -15, -16 and -24) have type 
1 transmembrane (TM) and cytosolic domains, whereas MMP-17 and - 25 have C-
terminal hydrophobic extensions that function as glycosylphosphatidylinositol (GPI)- 
anchoring signals116. The gelatinases (MMP-2 and MMP-9) have three repeats of 
type II fibronectin- like domains that bind to collagen, gelatin and laminin154, 155. 
 
1.6 MMP gene arrangement 
In addition to a common three-dimensional structure, MMPs have a similar gene 
arrangement, indicating that they probably arose by duplications of an ancestor 
gene156. At least eight of the known human MMP genes (MMP-1, -3, -7, -8, -10, -12, 
-13 and -20) are clustered on chromosome 11 at 11q21- 23, whereas other MMP 
genes are ‘scattered’ along chromosomes 1, 8, 12, 14, 16, 20 and 22 157. 
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1.7  Activation of MMPs  
MMPs are secreted in latent form as proenzymes, which require activation. MMPs 
become activated following a disruption of the bond between the thiol group of the 
conserved cysteine moiety (Cys73) of the propeptide domain and the active site Zn2+ 
of the catalytic domain (cysteine switch mechanism)144. A water molecule then binds 
to the Zn2+ ion and replaces the cysteine residue after the dissociation. The 
noncatalytic zinc is then switched to a catalytic one resulting in an intermediate 
active enzyme148, 158. In addition, the propeptide domain of the MMP is removed by 
autolytic cleavage or by other proteases. This cleavage causes a reduction in 
molecular mass by 8 -10 kDa and results in a fully active enzyme158.  
 
MMPs are generally activated by other proteinases in vivo. Several MMPs contain a 
furin cleavage site (RXKR or RRKR) between the propeptide and catalytic domains, 
which functions as a target sequence for pro-protein convertases or furins116. The 
cell-surface activation of proMMP2 by active MMP14, non-furin proMMP activation 
mechanism has been described in detail159-162.  
 
In vitro, MMPs are also activated by chemical and physical agents such as amino-
phenylmercuric acetate (APMA), low pH, and heat treatment 106, 120, 148. Additionally, 
it has been demonstated in vitro, that during inflammation oxidants generated by 
leukocytes or other cells can both activate MMPs (through oxidation of the 
propeptide domain thiol group) and subsequently inactivate MMPs (through 
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modification of amino acids that are crucial for catalysis), providing a mechanism to 
control huge surges of proteolytic activity163, 164.  
 
1.7.1  Regulation of MMP activity 
  
The catalytic activity of MMPs  is tightly regulated at multiple levels including gene 
expression (transcription and translation), compartmentalization, zymogen 
activation, inhibition by their endogenous inhibitors, the TIMPs and substrate 
availability and affinity109, 120, 165-167.  Recently, epigenetic modifications have been 
shown to contribute to MMP regulation168. 
 
MMPs are expressed at very low levels in normal healthy tissues. In contrast, MMP 
expression can be detected in all repair or remodelling processes, in all diseased or 
inflamed tissues and in all cell types grown in culture116. As a result of these different 
patterns and levels of MMP expression, it is expected that activated cells either in a 
tissue or culture express MMPs. The transcript levels are regulated by specific 
signals that are temporally limited and spatially confined116. 
 
Latent MMPs are kept in a catalytically inactive state by the sulfurhydryl bond 
between the conserved cysteine moiety (Cys73) of the propeptide domain and the 
active site Zn2+ of the catalytic domain. By the “cysteine switch mechanism”144 pro-
MMPs are converted to active enzymes. After the propeptide domain has been 
cleaved, the active MMPs can be inhibited by their natural inhibitors, the TIMPs and 
internalization169.  
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Compartmentalization (that is, where and how in the pericellular environment an 
MMP is released and held) is important for regulating the specificity of proteolysis 
and the affinity of the enzyme-substrate interaction116. Some MMPs are anchored to 
the cell membrane, thereby maintaining a high enzyme concentration locally and 
targeting their catalytic activity to specific substrates in the pericellular space116. In 
addition, specific cell–MMP interactions have been suggested to function as 
accessory factors that mediate the activation of the pro-enzyme and the binding of 
both substrate and MMP, thereby increasing the probability of proteolysis116. For 
example the binding of MMP2 to the v 3-integrin170, MMP1 to the 2 1-integrin171, 
172, MMP9 to CD44173  and MMP7 to surface proteoglycans174, 175.  
 
1.8  Genetic knockout of MMPs in mice 
MMPs have distinct but often overlapping substrate specificities in vitro176, inferring 
possible genetic redundancy in vivo152. At least 14 mouse MMP mutants have been 
generated: Mmp-2, 3, 7, 8, 9, 10, 11, 12, 13, 14 19, 20, 23, 24, and 28. The initial 
characterization of these knockout mice has shown obvious postnatal phenotypes, 
with all MMP-knockout lines surviving to birth (reviewed by Page-McCaw, Ewald and 
Werb,2007152). Mouse MMP double mutants have also been generated for 
Mmp2/Mmp-9177, Mmp2/Mmp14178 and  Mmp13/Mmp9179.  The functional role of 
MMP-13 in liver fibrosis and skeletal development has been studied employing 
MMP-13 KO mice180-184. Liver fibrosis was attenuated in MMP-13 KO mice180, 
however MMP-13 null mice showed profound defects in growth plate cartilage, 
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delayed endochondral ossification and bone remodelling181, 182, 184.  However, the 
role of MMP-13 in lung fibrosis remains to be established.  
 
1.9  Tissue inhibitors of metalloproteinases 
 
Tissue inhibitors of metalloproteinases (TIMPs) are specific regulators of MMP 
activity that bind and inhibit their specific active MMPs in a 1:1 stoichiometry120. The 
TIMP family consists of four members (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) that 
have been identified in vertebrates185. Their expression is regulated during 
development and tissue remodeling. TIMPs have been shown to bind to the 
proenzyme forms of MMP-2 186, 187 and MMP-9 150, 187 with high degree of specificity, 
an interaction that provides an extra level of regulation by preventing activation. 
Moreover, TIMP-1 and TIMP-2 are capable of inhibiting the activities of all known 
MMPs and as such play a key role in maintaining the balance between extracellular 
matrix deposition and degradation in different  physiological processes185. Under 
pathological conditions associated with unbalanced MMP activities, changes of 
TIMP levels are considered to be important because they directly affect the level of 
MMP activity188. 
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 1.9.1 Structure and Biological Functions of TIMPs 
 
TIMPs (21 to 29 kDa) have an amino (N)-and carboxy (C)-terminal domain of 
approximately 125 and 65 amino acids, respectively, with each containing three 
conserved disulfide bonds189, 190.  The N-terminal domain folds as a separate unit 
and is capable of inhibiting MMPs189. In 1994, the structure of the N-terminal domain 
of TIMP-2 was first resolved by nuclear magnetic resonance (NMR)191. The 
complete structure of TIMP-1 and of its mechanism of inhibition was determined in 
1997 by X-ray crystallographic studies of the TIMP-1–MMP-3 complex192, and that of 
the TIMP-2–MT1-MMP complex was determined soon after this193. The overall 
shape of the TIMP molecule is like a wedge, which slots into the active-site cleft of 
an MMP in a manner similar to that of the substrate193.  
 
TIMP-1 is also called erythroid potentiating activator (EPA), fibroblast collagenase 
inhibitor or collagenase inhibitor194. It is a 184 amino acid glycoprotein of 28.5 kDa. It 
has 41% sequence homology with the non-glycosylated 21.5 kDa TIMP-2 protein119, 
195, 196. TIMP-1 has been located in the nucleus of fibroblasts, or shown to bind to the 
cell surface of MCF-7 breast carcinoma cells and subsequently translocates to the 
nucleus197, 198. It is expressed by all cell types and as such is more widely distributed 
than the other TIMPs194. It forms a non-covalent, stoichiometric complex with both 
latent and active MMPs and inhibits the activity of all active MMPs 196. TIMP-1 
preferentially binds and inhibits proMMP-9 (Kd ≈35nM)187. Its binding to MMP-9 
occurs via a reversible non-covalent binding to the catalytic domain of the MMP 
protein187. It is not cleaved by the binding process and may be recovered with full 
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activity from complexes with MMP-3 192. In addition to its MMP-inhibitory role, TIMP-
1 has also been demonstrated to have erythroid-potentiating 194, 199 and cell growth - 
promoting activities200.  
 
TIMP-2 (also called CSC-21K) is a 194 amino acid unglycosylated protein of 21.5 
kDa that has 41% and 44% sequence homology to TIMP-1 and TIMP-3, 
respectively119, 195, 196. It is expressed by a variety of cell types, forms a non-covalent 
stoichiometric complex with both latent and active MMPs, inhibiting all active MMPs, 
showing a preference for MMP-2. It regulates the activation of proMMP-2 by binding 
to its C-terminal domain (Kd ≈ 5nM) 186. Likewise to TIMP-1, TIMP-2 also has 
erythroid - potentiating activity and cell growth–promoting activities 194, 199 and both 
TIMP-1 and TIMP-2 have been shown to have anti-apoptotic activity201-203. TIMP-2 
equally inhibits endothelial cell growth induced by basic fibroblast growth factor204. 
 
TIMP-3 is a 27 kDa glycoprotein (24 kDa unglycosylated), constitutively expressed 
by many cells in culture and has a markedly high expression in the eye205. It has a 
more basic Ki than other TIMPs and differs from them because it is localized to the 
extracellular matrix 196, 206. TIMP-3 also forms a non-covalent stoichiometric complex 
with both latent and active MMPs, and inhibits the activation of proMMP-2 by MT5-
MMP (MMP-15) 207. Sorsby’s fundus dystrophy, an autosomal dominant form of 
blindness due to macular degeneration, is reported to be caused by mutation in the 
gene encoding TIMP-3. Mutations are all found in the C-terminal domain and include 
the substitution of a residue for a cysteine, a nonsense mutation, or a splice 
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mutation, resulting in the deposition of the mutant TIMP-3 in Bruch’s membrane 208-
210. In addition, TIMP-3 has pro-apoptotic activity, possibly through the stabilization 
of TNF-α cell receptor 1, Fas, and TNF-related apoptosis, inducing ligand receptor-
1, as shown for some tumor cells 211, 212. Furthermore, overexpression of TIMP-1, 
TIMP-2, and TIMP-3 reduces tumor growth 213. These activities are also distinct from 
MMP inhibition and their mechanisms of action are yet to be resolved. 
 
TIMP-4 is a 24 - 29 kDa glycoprotein. It shows 37 % amino acid homology to TIMP-1 
and 51 % homology with TIMP-2 and TIMP-3 214. TIMP-4 is secreted extracellularly, 
predominantly in heart and brain tissue. It may function in a tissue specific fashion in 
extracellular matrix homeostasis. TIMP-4 binds to the proMMP-2 hemopexin-like 
domain and inhibits MT1-MMP but unlike TIMP-2 it neither forms a trimolecular 
complex nor activates pro-MMP-2 189, 215. TIMP-4 has a strong inhibitory effect on the 
invasion of human breast cancer cells across reconstituted basement membranes 
suggesting that TIMP-4 may have an important role in inhibiting primary tumor 
growth and progression216, 217.  
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1.10 Hypothesis 
  The expression level and spatial distribution of MMPs, especially the collagenases,  
largely determines the collagen deposition and the ultrastructural changes in  fibrotic 
lung diseases. 
 
 1.10.1  Aims and Objectives 
This study aims to define the spatial expression and the nature of MMP activity in 
IPF versus donor lungs, the contribution of TIMPs in the local inhibition of MMPs and 
the relative contribution of single MMPs in the process of  fibrotic repair. 
 
In this light, the first goal was to characterize the cell-specfic distribution and 
expression, and the activation status of MMPs [collagenases, gelatinases, matrilysin, 
macrophage metalloelastase, membrane type matrix metalloproteinases (MT-
MMPs)] and TIMPs in lungs from IPF patients and from organ donors.  
 
The second goal of the study was to further investigate the pathomechanistic role of 
collagenases in fibrotic lung diseases. Mice lack the orthologue of human MMP-1. 
Therefore, we further investigated the relevance of MMP-13 in context of fibrotic lung 
diseases by examining the fibrogenic response to bleomycin in MMP13-/- mice and 
their wild type littermates. 
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2.  MATERIALS 
2.1.  Chemicals 
 1-Propanol Merck KGA, Darmstadt, Germany 
2-mercaptoethanol Sigma-Aldrich, St.Loius, MO, USA 
2-methoxyethanol, ReagentPlus® Sigma-Aldrich, St.Loius, MO, USA 
3,4-Dehydro-DL-proline  
(C5H7O2  FW113.1) 
Sigma-Aldrich, Germany 
Acetic acid Merck KGA, Darmstadt,  Germany 
Acetone Merck KGA, Darmstadt,  Germany 
Acetonitrile (Lichrosolv®) for HPLC Merck KGA, Darmstadt,  Germany 
Acrylamide-Bisacrylamide BioRad Laboratories, Hercules,CA, U.S.A 
Agarose Sigma-Aldrich, St.Loius, MO, USA 
Ammonium persulphate Sigma-Aldrich, St.Loius, MO, USA 
Bovine serum albumin  Fraction V Carl Roth GmbH & Co.,Germany 
Bromophenol blue Fischer Scientific, NJ, U.S.A 
BSA Protein assay Kit Pierce, Rockford, IL, U.S.A 
Calcein-AM, C3099 Molecular Probes, Oregon, U.S.A 
Calcium Chloride dihydrate Merck KGA, Darmstadt,  Germany 
Captopril Fagron GmbH, Barbüttel 
Chloramine -T hydrate Sigma-Aldrich, St.Loius, MO, USA 
Dabsyl chloride (DABS-Cl) Sigma-Aldrich, Germany 
Deoxycholic acid sodium salt Fluka AG Chemicals, Germany 
Dimethylsulfoxide Merck KGA, Darmstadt,  Germany 
Dodecyl sodium salt (SDS) Sigma-Aldrich, St.Loius, MO, USA 
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Enhanced Chemiluminescence (ECL)™ 
Plus reagents 
GE Healthcare Ltd, Buckinghamshire, United 
Kingdom 
Ethanol Carl Roth GmbH & Co., Germany 
Gelatin type A from Porcine skin Sigma-Aldrich, St.Loius, MO, USA 
Glycin Carl Roth GmbH & Co., Germany 
Heparin Roche, Basel, Switzerland 
LMP-Agarose (ultra pure) Roche, Basel, Switzerland 
L-Proline Sigma-Aldrich, Germany 
Methanol Merck KGA, Darmstadt,  Germany 
N,N - Dimethylformamide HPLC Gr Merck KGA, Darmstadt,  Germany 
Normal Goat Serum Alexis Biochemicals, Grünberg, Germany 
ortho-Phthalaldehyde (OPA) Sigma-Aldrich, Germany 
p-amino phenyl mercuric actetate Calbiochem, USA 
Ponceau S solution Fluka AG Chemicals, Germany 
Porcine Gelatin for electrophoresis Sigma-Aldrich, St.Loius, Missouri, USA 
Potassium chloride for analysis Merck KGA, Darmstadt,  Germany 
Potassium dihydrogen phosphate Merck KGA, Darmstadt,  Germany 
Protease Inhibitor cocktail Roche Applied Sc., Minneapolis, USA 
Rat tail collagen type 1 BD Biosciences, MA, U.S.A 
Restore™ W. Blot Stripping Buffer Pierce, Rockford, IL, U.S.A 
RNeasy® Mini Kit Qiagen, Valencia, CA, U.S.A 
SERVA Blue G SERVA Biochemika, Heidelberg, Germ. 
Skimmed milk powder BioRad Laboratories, CA, U.S.A 
Sodium azide (ultra pure) Merck KGA, Darmstadt,  Germany 
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Sodium Chloride Carl Roth GmbH & Co., Germany 
Sodium Citrate Sigma-Aldrich, St.Loius, MO, USA 
Sodium dihydrogen phospahate Fisher Scientific GmbH, Germany 
Sodium hydrogen carbonate Merck KGA,  Darmstadt,  Germany 
TEMED  BioRad Laboratories, Hercules,CA, U.S.A 
Trans-4-hydroxy-L-proline  Sigma-Aldrich, Germany 
Triethylamine Sigma-Aldrich, St.Loius, MO, USA 
TRIS-HCl Carl Roth GmbH & Co., Germany 
Triton-X-100 Sigma-Aldrich, St.Loius, MO, USA 
Tween-20 Sigma-Aldrich, St.Loius, MO, USA 
Zinc Chloride Sigma-Aldrich, St.Loius, MO, USA 
 
 
2.2 Injecting solutions and substances 
Solution/ Substance Manufacturer 
Albumin, FlTC conjugate from bovine Sigma-Aldrich, St.Loius, MO, USA 
Bleomycin sulphate ® Sigma-Aldrich, St.Loius, MO, USA 
Enrofloxacine  
(Oral solution Baytril 2,5%®) 
Bayer Vital GmbH, Leverkusen, Germany 
Isofluorane Forene® Abbott, Wiesbach, Germany 
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2.3 Consumables  
 
Material Manufacturer/Supplier 
0.5ml, 1ml, 1.5ml , 2ml Eppendorf tubes Eppendorf, Germany 
 
1.8ml brown glass vials with caps VWR International, Darmstadt, Germany 
10ml,15ml, 50ml Falcon tubes Becton Dickinson Biosciences, Germany 
2ml, 5ml, 10ml, 25ml disposable  
pipettes 
Becton Dickinson Biosciences, Germany 






5 x 4 cm Purzellin® 
Lohmann und Rauscher 
Rengsdorf, Germany 
Gauze balls size 6 
 
Fuhrman Verrbandstoffe GmbH 
Much, Germany 
Heating pad Thermo-Lux® Witte und Suttor, Murrhardt, Germany 
Hybond-C polyvinylidene difluoride 
(PDVF) membrane 
Amersham Biosciences, GE Healthcare, 
Buckinghamshire, United Kingdom 
Medical adhesive bands Durapore®  3M Company, St. Paul, MN, USA 
Pyrex glass tubes (15ml) VWR International, Darmstadt, Germany 
Napkins Tork, Mannheim, Germany 
 
Needles 26G (0,9mm x 25mm)  Becton Dickinson Biosciences, Germany 
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BD Microlance 3® 
Perfusor-tubing 
150 cm Original-Perfusor®-tubing 
Braun, Melsungen, Germany 
Respirator N95 Particulate  3M Canada Company, Ontario, Canada 
Single use gloves Transaflex® Ansell, Surbiton Surrey, UK 
Single use syringes 1ml, 2ml, 5ml, 10ml 
Inject Luer® 
Braun, Melsungen, Germany 
Surgical instruments Martin Medizintechnik, Tuttlingen, Germany 
Centricon®  Centrifugal Filter devices 
Centricon YM-10 
Millipore Corporation, Bedford, MA, U.S.A 
Surgical threads non-absorbable 
Size 5-0 ETHIBOND EXCEL® 
Ethicon GmbH 
Norderstedt, Germany 
Surgical threads with needle 
Size 5-0, 6-0 and 7-0 ProleneTM 
Ethicon GmbH, Norderstedt, Germany 
Threads Nr. 12 Coats GmbH, Kenzingen, Germany 
Tracheal cannula, 20G Becton Dickinson/ MEDEX Inc. 
Carlsbad, CA, U.S.A 
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2.4   Histology  
 
Material Company 
Automated Cryotome Leica Microsystems, Nussloch, Germany 
Automated microtome RM 2165 Leica Microsystems, Nussloch, Germany 
Cooling plate EG 1150C Leica Microsystems, Nussloch, Germany 
Cover slips 24x36mm VWR, Menzel, Germany 
Digital Camera Microscope DC 300F Leica Microsystems, Nussloch, Germany 
Eosin Y solution, alcoholic Sigma Diagnostics®,St. Loius, MO, U.S.A 
Flattening bath for paraffin sections HI 
1210 
Leica Microsystems, Nussloch, Germany 
Flattening table HI 1220 Leica Microsystems, Nussloch, Germany 
Formaldehyde alcohol free ≥37% Roth, Karlsruhe, Germany 
Graded Ethanol 70%, 95%, 99,6% Fischer, Saarbrücken, Germany 
Histological glass slides Superfrost 
Plus® 
R. Langenbrinck, Emmendingen, Germany 
Hydrogen peroxide 30% pro analysi Merck Darmstadt, Germany 
Isopropanol (99,8%) Fluka Chemie, Buchs, Swiss 
Kernechtrot Aluminium sulfate Chroma, Münster, Germany 
Mayer’s Hematoxylin solution Sigma-Aldrich, St. Loius, MO, U.S.A 
Methanol, HPLC Grade Fischer Scientific, New Jersey, U.S.A 
Microtom blades S35 Feather Safety Razor Co.Ltd, Japan 
Mounting medium Pertex® Medite GmbH Burgdorf, Germany 
Paraffin Allegiance Health Care, Corp. IL, U.S.A 
MATERIALS               2.4 Histology 
 
 Regulation and pathomechanistic role of matrix metalloproteinases in idiopathic pulmonary fibrosis   51
Paraffin embedding medium Paraplast 
Plus® 
Sigma Aldrich,Steinheim, Germany 
Picric acid Fluka Chemie, Buchs, Swiss 
Resorcin Fuchsin Chroma, Münster, Germany 
Roti-Histol (Xylolersatz) Roth, Karlsruhe, Germany 
Shandon Cytospin 4  Thermo Electron Corporation, Waltham, 
U.S.A 
Stereo light microscope DMLA Leica Microsystems, Nussloch, Germany 
Tissue embedding machine EG 1140H Leica Microsystems, Nussloch, Germany 
Tissue processing automated machine 
TP 1050 
Leica Microsystems, Nussloch, Germany 
Universal-embedding cassettes Leica Microsystems, Nussloch, Germany 
Urine pots with covers, 100ml Corning Incorporated, Mexico 
Van Giesson’s solution Polyscientific, Bay Shore, NY, U.S.A 
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2.5  Antibodies  
Antibody Catalogue Number & Description Company 
Anti-ß-actin (AC-15), 
mouse monoclonal  
AB6276; loading control; recognizes 
42kDa human ß- actin 
Abcam, Germany 
Actin (C-11), loading 
control, goat polyclonal 





Anti-MMP-1 (Ab-1) ; 
monoclonal,  
mouse anti-human 
IM35L; recognizes both latent 






(Ab-3) ; monoclonal 
mouse anti-human 
IM33L; recognizes both latent (72kDa) 




Anti-MMP-7 (Ab-4) ; 
rabbit polyclonal 
PC492; recognizes the ~ 28 kDa latent  





Anti-MMP-8 (Ab-1) ; 
mouse monoclonal 
antibody (115-13D2) 
IM38L; recognizes the ~ 85kDa latent  





Anti-human MMP-9 ; 
goat polyclonal antibody 
AF911; recognizes human and mouse 
pro (92kDa) and active (86kDa) MMP-9. 
R&D Systems 
GmbH, Germany. 
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Anti-MMP-13 (Ab-4) ; 
mouse monoclonal 
antibody (VIIIA2) 
IM78; recognizes both  the ~ 60 kDa 
















Anti-TIMP-2 (Ab-2) ; 
mouse monoclonal 
antibody (67-4H11) 








IM43L; recognizes both the ~ 27kDa 
glycosylated and the ~ 24kDa 







AF974; recognizes human TIMP-4 
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2.6  Machines, systems and software 
Machine/System/Software Company 




Applied Biosystems’ 7500 Real-Time 
PCR System 
Applied Biosystems, Foster City, CA, U.S.A 
Biorad 200/2.0 electrophoresis power 
supply 
BioRad, Hercules, CA, U.S.A  
 
BioRad iCyclerTM 96 well Reaction 
Module 
BioRad, U.S.A 
Computer Q 550 IW Leica Microsystems, Nussloch, Germany 
Consort EV 231 Elect. Power Supply Belgium 
Eppendorf BioPhotometer Eppendorf, Hinz GmbH, Germany 
Eppendorf Centrifuge 5417R Eppendorf, Hinz GmbH, Germany 
FluorochemTM 8900 Alpha Innotech, San Leandro, CA, U.S.A 
Gel Logic 2000 Imaging System  Carestream/Kodak Molecular Imaging 
System, CT, U.S.A 
H1221 pH meter HANNA INSTRUMENTS GmbH, 




Hettich Zentrifugen Universal 30 RF Tuttlingen, Germany 
HP Chem Station for LC and LC/MS  
systems 
Agilent Technologies Waldbronn, Germany 
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Intrapulmonary Aerosolizer: Series IA-
1C Microsprayer™ with series FMJ-250 
High-Pressure Syringe 
Penn-Century, Inc, Philadephia, PA, U.S.A 
Labnet Shaker 35 Labnet International Inc, NJ, U.S.A 
Lichrosorb RP18  RP-HPLC column Merck KGA, Darmstadt, Germany 
LYPH.LOCK6 Freeze Dry System Labconco Corp., MO, U.S.A 
Mettler Toledo AB 54 Balance Mettler Instrument Corp., Switzerland 
Mettler Toledo AG 285 Balance Mettler Instrument Corp., Switzerland 
Mettler Toledo MX5 Balance Mettler Instrument Corp., Switzerland 
Mettler Toledo PB 801 Balance Mettler Instrument Corp., Switzerland 
PowerPac Basic, BioRad BioRad, Hercules, CA, U.S.A 
Primer Express® Software Version 3.0 Applied Biosystems, Foster City, CA, U.S.A 
Scotsman’s Ice machine Scotsman Ice Sytems, IL, U.S.A 
Software Q Win V3 Leica Microsystems, Nussloch, Germany 
SPOT ™ 2.3.0 software Diagnostic Systems Inc, MI, U.S.A 
Tecan Spectra Fluor⊕, Magellan™ Tecan Austria GmbH 
TJ 25 Centrifuge Beckman Coulter™, U.S.A 
Trans-Blot SD Semi-dry Transfer Cell BioRad, Hercules, CA, U.S.A 
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3. METHODS 
 
3.1  Human Lungs 
 
3.1.1 Study Population and Specimen Collection 
 
The study was approved by the local ethics committee, and informed consent was 
obtained from all study subjects. Explanted lungs (n=16 for sporadic IPF) or non-
utilized donor lungs or lobes fulfilling transplantation criteria (n=6; human donors, 
HD) were obtained from the Dept. of Thoracic Surgery in Vienna, Austria. All IPF 
diagnoses were made according to the Consensus Conference criteria14 and a UIP 
pattern was proven in all IPF lungs. All IPF subjects experienced progress under a 
preceding course of steroids.  
All lungs or lobes of normal tissue were taken from donors who died from brain 
death. The lungs fulfilled selection criteria for organ transplantation but were not 
transplanted due to technical reasons. Donor lobes were obtained when donor lungs 
needed to be reduced by size in order to be compatible with recipient’s anatomical 
dimensions. Informed consent was obtained at the time of transplant evaluation. 
Donor lungs had no evidence of active infection, chest radiographic abnormalities, 
and no past medical history of underlying systemic or lung disease. Two additional 
control samples were purchased: a pool of total RNA from six normal lungs obtained 
from CLONTECH and total RNA from one normal lung from AMBION.  
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IPF and donor lungs were transferred from Vienna (Department of Thoracic Surgery, 
Vienna General Hospital, Vienna, Austria) to Giessen (Univerisity of Giessen Lung 
Center) on crushed ice, after being flushed with preserving solution. In addition, at 
the surgical theater in Vienna, samples were obtained and snap-frozen in liquid 
nitrogen. In Giessen, the lungs were processed following a predefined algorithm and 
samples were stored at -80°C. 









 Figure 5: Schematic diagram showing IPF lung tissue dissection. 
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Table 4 depicts which lung tissues were used as controls for the specific analysis. 
Table 4: Overview of control specimen used in this study 
Method IPF Control 
Histology C1 - C3 Vienna donor lung/lobe 








Vienna donor lung/lobe 
Commercial RNA from Ambion and Clontech 
Western blot C1  Vienna donor lung/lobe 
Gelatin  zymography C1  Vienna donor lung/lobe 
Collagenase activity C1 Vienna donor lung/lobe 
Immunohistochemisty C1 Vienna donor lung/lobe 
In situ zymography C1 Vienna donor lung/lobe 
 
3.2  Animals 
MMP-13-/- and wild type littermates were generated from the intercross between 
heterozygous MMP-13 +/- mice in a C57BL/6J and 129/Sv hybrid background. 
Generated MMP-13-/- mice were genotyped by Southern blotting and by PCR 
analysis as described elsewhere180. Mice received food and water ad libitum, and 
were kept under controlled light (12/12-hours light/dark cycle) and temperature (16° -
25°C) throughout the experimental period. All experiments were performed 
according to the protocol approved by the Institutional Laboratory Animal Care and 
Use Committee of Columbia University in the City of New York. Animals received 
humane care according to the criteria outlined in the “Guide for the Care and Use of 
Laboratory Animals”.
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3.3 Induction of pulmonary fibrosis in mice by bleomycin treatment. 
Eight to twelve week-old and gender-matched MMP-13-/- and wt littermates were 
used in the study. Pulmonary fibrosis was induced in mice by intratracheal 
administration of a single dose of bleomycin sulphate (5U /kg body weight), 
reconstituted in 0.9% NaCl solution. Control animals received 0.9% NaCl 
intratracheally. The solution was aerosolized by use of a microsprayer at a volume of 
200µl. For the analyses, mice were euthanized 7, 14 and 28 days after bleomycin or 
saline administration. Unless otherwise specified, for every variable analyzed, five 
control and experimental mice were used. The experimental protocol for the mouse 








Figure 6: Schematic protocol for mouse experiments. Mice were euthanized 
at d7, d14 and d28 after bleomycin or saline administration. Samples were 
retrieved for analyses; n= number of mice in the group.
MMP-13-/- and WT mice (n=5 each) 
Readout at d7, d14, d28 
 
Lung compliance 
BALF cell count 
Histology 
Hydroxyproline assay 
MMP and TIMP expression analyses 
MMP activity analyses 
 5U bleomycin per kg body weight or equivalent volume of 
saline (control) as intratracheal aerosol application 
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3.4 Quasi-static lung compliance 
To determine the pulmonary compliance of the lung, an open-chest model was used as 
previously described 218  and the quasi-static lung compliance was measured using the 
Flexivent apparatus (SCIREQ, Inc. Montréal, Québec, Canada). Briefly, mice were 
euthanized by CO2 asphyxia and after a careful tracheotomy; a 20-gauge catheter was 
inserted into the trachea and secured with a silk suture. A mediastinal dissection was 
performed, and the anterior chest wall was completely resected. Before lung compliance 
measurements, the Flexivent apparatus was calibrated for a transpulmonary pressure-
volume (PV) of 30cm H2O; a water manometer was connected in circuit with a tube that 
was inserted into the three-way stopcock into which the flexivent’s plastic tubing had 
also been inserted. The flexivent plastic tubing was inserted into the tracheal cannula 
and an attached 10ml syringe was used to install the desired volume of air. Three 
measurements were taken per animal with a 30s interval between each measurement. 
The quasi static pressure-volume curve for each measurement was digitally converted 
by the instruments software. Data from each pressure-volume curve were collected, and 
pooled mean pressure-volume (quasi-static expiratory compliance (Ecst) parameters 
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3.5  Bronchoalveolar lavage  
Euthanized mice with a tracheal cannula inserted as described above were carefully 
lavaged with 1ml of PBS twice, so that ~ 2ml of bronchoalveolar lavage fluid (BALF) 
were recovered from each mouse. The BALF was centrifuged at 300g for 10 minutes 
at 4°C, and the supernatant was aliquoted and frozen at -80°C until analysis. Total 
cell counts were performed on the cell pellets employing an improved Neubaur 
hemocytometer. Cells were then cytospun at 700 r.p.m for 3 minutes (Cytospin 3®, 
Thermo Shandon, Ltd, Astmoor, United Kingdom) and stained with a modified 
Wright’s stain (DiffQuik, American Scientific Products, McGaw Park, IL). Differential 
cell counts were performed on 200 cells using standard morphological criteria as 
described elsewhere90. 
3.6  Processing of human and murine lungs  
Shock-frozen tissue and paraffin sections were prepared from explanted human 
lungs immediately after retrieval. For paraffin sections, human tissues were fixed by 
submersion for 72h at RT and murine lungs were perfused via vasculature at 
25 cmH2O followed by submersion for 24h at RT in 10% neutral buffered formalin. 
Sections were dehydrated through a series of graded ethanol and xylene, and 
embedded in paraffin. 3µm thick paraffin sections were cut, transferred onto glass 
slides and incubated overnight at 37°C. For frozen sections of human lungs, the lung 
samples were snap-frozen in liquid nitrogen already at the surgical theatre and 
stored at -80°C.  For frozen sections, murine lungs were distended to total lung 
capacity with Tissue-Tek® OCT compound, removed en bloc, snap-frozen in liquid 
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nitrogen and stored -80°C. 10µm thick sections were cut by cryostat, transferred 
onto superfrost glass slides, air dried and stored at -20°C. 
 
3.7  Gelatin  zymography in murine BALF samples 
Bronchoalveolar lavage fluid (BALF) was pooled from experimental animals at the 
indicated time points, concentrated five-fold using YM-10 Centricon centrifugal filters 
and the total protein concentration was measured with the BCA protein assay kit. 
50µg of BALF total protein was mixed with 4x Laemmli sample buffer without ß-2-
mercaptoethanol and in absence of boiling, and the proteins were separated in non-
reducing, 10 % polyacrylamide gel copolymerized with 1 mg/mL of porcine skin 
gelatin. After electrophoresis (100V, 1h) SDS was removed from the gels by two 
washes in 2.5% Triton X-100, 30 minutes each time. Subsequently, the gels were 
equilibrated in developing buffer (50 mM Tris [pH 7.4], 10 mM CaCl2, 1µM ZnCl2, 1% 
Triton-X-100) for 30 minutes, then incubated in fresh developing buffer at 37°C for 
18 hours. The gel was stained with 0.5% Coomassie Blue R-250 for 1 hour, followed 
by destaining (20% methanol, 20% ethanol, 7% acetic acid). Gelatinolytic activity 
was detected as clear bands on a dark blue background. The protein molecular 
weight marker and specific recombinant gelatinases were included in the gel for 
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3.8 Macrophage Chemotaxis to BALF samples 
 BALF that served as the chemoattractant was retrieved from experimental animals 
at d7. Fluorescently labeled alveolar macrophages (AMJ2-C11 macrophage cell line 
[ATCC]) served as the target cells.  BALF was diluted 8-fold and 29µl was placed in 
the bottom chamber of a 96 well chemotaxis chamber (101-5, Neuroprobe, Inc.) and 
28 µl of serum-starved macrophages at 1.5 x 104 cells/ml was placed on  top of the 
filter above its corresponding well so that  beads were formed. After 1 hour of  
incubation at 37°C at 5% CO2 the number of macrophages that migrated into the 
lower chamber was determined by reading the fluorescence intensity using a 
fluorescent plate reader (Ex/Em = 485/530nm). Results are reported as the directed 
versus random migration ratio; i.e, the ratio of the intensity of fluorescence in the test 
wells to that of the blank (wells containing only media). 
 
3.9   Analysis of collagenase activity in human lung homogenates 
Collagenase activity in human lung homogenates was determined using the 
EnzChek® Gelatinase/Collagenase assay kit from Molecular Probes, with some 
modifications. As substrate, the DQ™ collagen, fluorescein conjugate called D-
12060 collagen, in which heavy labeling with fluorescein results in quenching of 
fluorescence was used. Briefly, a serial dilution of standard stock solution (500 U/ml) 
of collagenase, type IV from Clostridium histolyticum, was prepared in 1X reaction 
buffer (50mM Tris, 150mM NaCl, 5mM CaCl2, pH 7.6). 50µg protein in each lung 
homogenate was diluted to100µl in 1X reaction buffer. Wells of a black flat-bottom 
96-well optical bottom microtiter plate were coated (50 µl per well) with 100µg/ml of 
DQ-collagen in low gelling agarose, in the dark. After the agarose solidified, 100µl of 
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standards and 100µl of sample were added to the wells in triplicates followed by 
100µl 1X reaction buffer. For controls (blanks), 200µl 1X reaction buffer was added 
to coated and uncoated wells. Samples were incubated at 25°C, protected from light 
for 2 hours. The fluorescence intensity was read in a fluorescence microplate reader 
at Ex/Em of 495/515nm. For each standard and sample background fluorescence 
was corrected by subtracting values derived from the blanks.  A standard curve was 
obtained from the standard to confirm the linearity between collagenase activity and 
substrate degradation. Collagenase activity was calculated by the computer software 
(Magellan) and expressed as unit of activity per unit sample volume (mU/ml). 
3.10 Hydroxyproline determination in human lungs 
Hydroxyproline levels in human lung tissues were determined following the protocols 
of Ikeda219 and Sormiachi220. Human lung tissues in 1000µl of distilled H2O (dH2O) 
were thoroughly homogenized employing a Potter homogenizer. 500µl of each lung 
homogenate were transferred into pre-weighed and labeled 2ml eppendorff tubes 
and then dried for 12 h employing a speed vaccum and the lung dry weight was 
measured. The dry lung was hydrolyzed with 500µl of 6N HCl at 116°C for 16 h221.  
After cooling, a 1:10 dilution of each hydrolysate (10µl hydrolysate + 90µl dH2O) was 
prepared and 10µl of diluted hydrolysates were transferred to 1.8ml brown glass 
vials. External standard solutions (in duplicate) containing trans-4-hydroxy-L-proline 
and L-proline were prepared in 1.8ml brown glass vials at concentrations and 
volumes shown in Table 5. 
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Table 5: Trans-4-hydroxy-L-proline and L- proline external standards   
No. Hydroxyproline Proline 
1 50µl of 0.1µmol/ml 50µl of 0.1µmol/ml 
2 20µl of 0.1µmol/ml 20µl of 0.1µmol/ml 
3 10µl of 0.1µmol/ml 10µl of 0.1µmol/ml 
4 50µl of 0.01µmol/ml 50µl of 0.01µmol/ml 
5 20µl of 0.01µmol/ml 20µl of 0.01µmol/ml 
6 10µl of 0.01µmol/ml 10µl of 0.01µmol/ml 
7 5µl of 0.01µmol/ml 5µl of 0.01µmol/ml 
 
For derivatization, 20µl of triethylamine and 20µl of 0.1µmol/ml 3, 4-dehydro-DL-
proline (internal standard) were added to the diluted hydrolysates and external 
standards, and mixed. Then all the samples were frozen with liquid nitrogen and 
were dried under vacuum. To block the primary amino group, 20µl of 14.9 mM ortho-
pthalaldehyde (OPA) solution were added to the dried samples (lung hydrolyates or 
external standards), and mixed thoroughly. The solution was incubated for 5 min at 
room temperature, and then 20µl of dabsyl-Cl in acetonitrile (1.3mg/ml) were added 
to all samples solutions and mixed well. Dabsylation was performed for 20min at 
70°C with all vials capped. After 10 min at RT, 60µl of 50% acetonitrile in dH2O were 
added to the samples, mixed well and stored at 4°C until RP-HPLC analysis. The 
detection of dabsylated amino acids (secondary amino groups) was carried out at 
279.8nm and 436.8nm on the column, Merck Lichrosorb RP 18 (4.6 x 150mm, 
particle size 5µm). The column was maintained at 50°C and eluent flow-rate was 
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1.5ml/min.The gradient elution programme and mobile phases used for separating 
hydroxyproline, dehydroproline and proline are given in Table 6. 
  
Table 6: Gradient elution program for separation of hydroxyproline219, 220 
Time (min) Solvent A (%) Solvent B (%) 
0 - 3 55 (isocratic) 45 






12 -13 0 100 
13 -15 0 (isocratic) 100 
15 -15.5 55 45 
Solvent A: 40mM Na2HPO4 adjusted to pH 3.0 with ortho-phosphoric acid. 
Solvent B: 4% (v/v) dimethylformamide in acetonitrile-dH2O (4:1). 
A standard curve was obtained from the external standards. The hydroxyproline 
content of the lung hydrolysates was calculated using the HP Chem Station for LC 
and LC/MS systems software and expressed as microgram hydroxyproline per 
milligram lung dry weight (µg/mg). 
 
3.11 Hydroxyproline determination in murine lungs 
Hydroxyproline levels in murine lungs were determined following the protocol of 
Woessner222. The mouse lung tissue was homogenized in 500µl of distilled H2O 
(dH2O), then lyophilized for 12 h and the lung dry weight was measured. The dry
lung was hydrolyzed with 4 ml of 6N HCl at 116°C for 16 h. 2ml of the hydrolysate 
were evaporated and the powder was then reconstituted with 2ml of dH2O and then 
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re-evaporated. This powder was then reconstituted with 2 ml of dH2O and the pH 
adjusted to pH 7.0. Standard solutions containing 3, 4 D-L- hydroxyproline (Sigma) 
were made at concentrations of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 µg/ml. Sample 
solution (2 ml) was taken and oxidized with 1 ml of Chloramine-T (Sigma) for 20 min. 
The reaction was then stopped with 1 ml of 3.15 M perchloric acid.  After 5 min, 1 ml 
of p-dimethylaminobenzaldehyde solution was added. The sample was thoroughly 
vortexed until appearing lucent, incubated in a 60°C bath for 20 minutes, and then 
cooled under tap water for 5 min. The absorbence of the solutions was determined at 
557 mm. The hydroxyproline content of the lung samples was calculated from the 
standard curve and expressed as mg hydroxyproline per lung dry weight. 
3.12  Quantitative real time reverse transcription- polymerase chain reaction  
(RT-PCR) analysis. 
Total RNA was extracted from lung tissue using the Qiagen RNeasy® Mini kit, 
according to recommendations from the manufacturer. Briefly, snap frozen lungs 
were homogenized in buffer RTL containing 1% v/v ß- mercaptoethanol. After full 
speed centrifugation for 3 min, supernatants were collected and mixed with an equal 
volume of 70% ethanol (RNase-free). The mixture was added to an RNeasy mini 
column and centrifuged again. RNase-free DNase I was added to the filter 
membranes for ≥ 15 min at 20-30°C in order to eliminate contaminating genomic 
DNA. Following washes of the column RNA was eluted two times from the filter 
using 40µl of RNase free water each time. The RNA concentration and quality were 
assessed by measuring the A260 and A260/A280 respectively.  
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 2 µg of total RNA was reverse-transcribed using a first-strand cDNA kit with random 
hexamers (Applied Biosystems, Foster City, CA) according to the manufacturer’s 
recommendations.  Two negative controls, one without the RNA template and other 
lacking reverse transcriptase were included. Human MMP-1, MMP-2, MMP-7, MMP-
8, MMP-9, MMP-12, MMP-14, TIMP-1, TIMP-2, TIMP-3, and TIMP-4 as well as  
murine Mmp-7, Mmp-8, Mmp-13, Timp-1, Timp-2, Timp-3, and Timp-4 mRNA 
transcripts were quantified using Power SYBR Green® PCR  and with human and  
mouse smooth muscle actin (mACTB) as internal controls respectively for human 
and murine samples. Each sample was run in triplicates. The negative control 
reactions were also included. The PCR reaction and analyses were carried out using 
the ABI Prism 7500 Sequence Detector and software. The relative abundance of the 
target genes was obtained by calculating against a standard curve and normalized 
to an internal control. PCR primers were purchased from ABI TaqMan Gene 
Expression Assays (Applied Biosystems) and QuantiTect® Primer Assays (Qiagen).  
Table 7:  Primers used for the amplification of cDNA from human lung tissue  
 by Power SYBR Green® PCR 
cDNA Primer sequence (5’                     3’) 
(F = Forward primer; R = Reverse primer) 
hMMP-1 F: CCT CGC TGG GAG CAA ACA 
R: TTG GCA AAT CTG GCG TGT AA 
hMMP-2 F: CGT CTG TCC CAG GAT GAC ATC 
R: ATG TCA GGA GAG GCC CCA TA 
hMMP-7 F: GCT GGC TCA TGC CTT TGC 
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R: TCC TCA TCG AAG TGA GCA TCT C 
hMMP-8 F: CCC AAC TAT GCT TTC AGG GAA A 
R: GCC TGA ATG CCA TCG ATG T 
hMMP-9 F: GGA CGA TGC CTG CAA CGT 
R: CAA ATA CAG CTG GTT CCC AAT CT 
hMMP-12 F: TGC ACG CAC CTC GAT GTG 
R: GGC CCC CCT GGC ATT 
hMMP-13 F: TTC TTG TTG CTG CGC ATG A 
R: AGG GTC CTT GGA GTG GTC AA 
hMMP-14 F: TCA GGG TTC CCC ACC AAG A 
R: AAC AGA AGG CCG GGA GGT A 
hTIMP-1 F: CGC TGA CAT CCG GTT CGT 
R: TGT GGA AGT ATC CGC AGA CAC T 
hTIMP-2 F: GGG CAC CAG GCC AAG TT 
R: CGC ACA GGA GCC GTC ACT 
hTIMP-3 F: CCT GGC TAC CAG TCC AAA CAC 
R: TGC AGT AGC CGC CCT TCT 
hTIMP-4 F: GCA CCC TCA GCA GCA CAT C 
R: CTG GAG ATT TTG GCC CGA AT 
hß-actin 
(hACTB) 
F: GCG CGG CTA CAG CTT CA 
R: CTT AAT GTC ACG CAC GAT TTC C 
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Table 8:  Primers used for the amplification of cDNA from murine lung  
  by Power SYBR Green® PCR 
      
  Gene 
                      
                          Assay name 
Catalog 
number 
Mmp -7 Mm_Mmp7_1_SG Quantitect Primer Assay(200) QT00110012 
Mmp -8 Mm_Mmp8_1_SG Quantitect Primer Assay(200) QT00113540 
Mmp -13 Mm_Mmp13_1_SG Quantitect Primer Assay(200) QT00111104 
Timp -1 Mm_Timp1_1_SG Quantitect Primer Assay(200) QT00996282 
Timp -2 Mm_Timp2_1_SG Quantitect Primer Assay(200) QT00138558 
Timp -3 Mm_Timp3_1_SG Quantitect Primer Assay(200) QT00105469 
Timp -4 Mm_Timp4_1_SG Quantitect Primer Assay(200) QT00151844 
mß-actin 
(mACTB) 
Mm_Actb_2_SG Quantitect Primer Assay(200) QT01136772 
 
3.13  Western blot analysis of MMPs and TIMPs in human tissues 
Human lung tissue samples were pulverized in liquid nitrogen and incubated in RIPA 
buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1% (v/v) Triton-X-100, 1% 
NP-40, 0.1% SDS, 1mM PMSF, Complete protease inhibitor cocktail [Roche]). 
Protein concentrations were determined with the BCA Protein Assay Kit (Pierce, 
Rockford, IL). 50 µg total protein per sample were mixed with denaturing Laemmli 
sample buffer, electrophoresed on a 10% denaturating SDS-polyacrylamide gel and 
transferred onto polyvinylidene difluoride (PVDF) membranes using a semi-dry 
transfer cell. Non-specific sites on the membranes were blocked for 2 hours at room 
temperature with 5% (w/v) non-fat dried milk in TBS/T (Tris-buffered saline [TBS; 50 
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mM Tris-HCl, pH 7.5, 50 mM NaCl], and 0.1 % Tween 20). Membranes were 
incubated with primary antibody in 5% (w/v) non-fat dried milk in TBS/T at 4°C, 
overnight, with gentle shaking. Primary antibodies used were purchased from 
Calbiochem except otherwise indicated as shown in Table 9. Membranes were 
washed 3 x 15 minutes in 1 × TBS/T and incubated for 1 hour at room temperature 
with respective horse-radish peroxidase-conjugated secondary antibodies to mouse, 
goat and rabbit IgGs (1:2000 in 5% (w/v) non-fat dried milk in 1x TBS/T.
 
Table 9:  Antibodies and dilutions used in western blot 
Antibody Dilution used 
Monoclonal anti- human MMP-1 1:1000 
Monoclonal anti- human MMP-2 1:1000 
Rabbit polyclonal anti-human MMP-7 1:5000 
Monoclonal anti-human MMP-8 1:1000 
Goat polyclonal anti-human MMP-9 (R & D systems) 1:1000  
Monoclonal antibody to latent and active human MMP-13 1:500 
Monoclonal anti-human TIMP-1  1:500 
Monoclonal anti- human TIMP-2 1:500 
Monoclonal anti-human TIMP-4 (R & D systems) 1:500 
Monoclonal anti-human ß-smooth muscle actin (Abcam) 1:10,000 
  
After four washes with 1xTBS/T, membranes were developed with the Enhanced 
Chemiluminescence (ECL) Plus detection system using radiographic film. The band 
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intensity of exposed film was analyzed by densitometric scanning and quantified 
using AlphaEase®FC Imaging System. The density of the protein of interest was 
related to the density of the housing-keeping gene (β-actin). Experiments were 
repeated three times per each patient sample. 
 
3.14  Histopathology and Immunohistochemistry 
Formalin fixed, paraffin-embedded human and murine lung tissue sections were 
routinely stained with haematoxylin and eosin (H & E) stain and with Masson-
Trichrome stain in order to assess the histological phenotype and extent of collagen 
deposition. For each human patient or murine sample, 3 slides were analysed and 5 
random fields were examined. Immunohistochemistry for human MMP-13 and for 
murine MMP-7 was also performed on paraffin sections. Monoclonal anti-human 
MMP-13 antibody (5µg/ml) and goat anti-mouse MMP-7 antibody (15µg/ml) were 
primary antibodies for human and murine sections respectively. After 
deparaffinization and rehydration, endogenous peroxidase activity was quenched by 
treating tissue sections in 3% H2O2 in methanol. Antigens were retrieved by 
microwaving for 20 minutes in 10mM citrate buffer, pH 6.0 and cooling at RT. 
Sections were washed with phosphate-buffered saline (PBS, pH 7.4) and 
immunohistochemistry performed using the Labeled-[strept] Avidin-Biotin (LAB-SA) 
method according to the manufacturer’s recommendations. Briefly, non-specific 
background was eliminated by incubating sections with blocking solutions A and B 
for 30 min and 10 min, respectively, followed by overnight incubation  at 4°C with 
mouse anti-human MMP-13 (5µg/ml) [human sections] or goat anti-mouse MMP-7 
METHODS           3.15 IHC combined with ISZ 
 
 Regulation and pathomechanistic role of matrix metalloproteinases in idiopathic pulmonary fibrosis   73
(15µg/ml) [murine sections]. After three washes in PBS, a biotinylated secondary 
anti-IgG was applied followed by the streptavidin-peroxidase conjugate. The 
presence of peroxidase was revealed by adding the chromogenic substrate solution. 
The formation of a brown deposit demonstrates the location of the antigen and the 
reaction was terminated by washing in distilled water. Stained sections were 
counterstained with haematoxylin; slides were dehydrated with graded series of 
alcohol, cleared in xylene and mounted in HistomountTM. For negative control slides, 
the primary antibody was replaced by the corresponding non-immune serum.  
3.15  Immunohistochemistry combined with in situ zymography 
Immunohistochemical (IHC) localization of MMP-1 and MMP-9 protein was 
performed on 10µm cryostat sections of human lungs followed by in situ zymography 
(ISZ) in order to co-localize the MMP protein signal with the collagenolytic and 
gelatinolytic activity in the tissue. Briefly, cryostat sections were air-dried for 1 hour 
at RT and fixed with ice cold acetone for 10 min at RT. The IHC procedure for the 
desired antigen was performed according to standard procedures using a 
fluorescently labeled secondary antibody (rhodamine RedTM-X-conjugated) with 
spectral properties other than FITC. Non-specific antigenic sites were blocked with 
5% goat serum in TBS at 4°C for 1 hour. Sections were incubated at 4°C overnight 
with primary antibody in TBST containing 1% goat serum. Control sections were 
incubated with the corresponding non-immune serum. After 3 x 5min washes with 
TBS, sections were incubated at 4°C for 90min with rhodamine RedTM-X-conjugated 
secondary antibody in TBST containing 1% goat serum. ISZ was then performed in 
order to localize collagenolytic and gelatinolytic activity in the lung tissue223, 224. 
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Briefly, sections were overlaid with 1 % low gelling temperature (LGT) agarose 
containing 100µg/ml highly quenched FITC-labeled DQ-collagen or DQ–gelatin, 
covered with a coverslip and gelled at 4°C. Sections were incubated at 37°C for 12 
hours and examined. Control incubations were performed on serial cryostat sections 
by adding 30mM Captopril to the incubation medium. The presence of auto-
fluorescence in sections was tested by incubating in agarose-containing medium 
lacking DQ-collagen or DQ-gelatin. Nuclei were counterstained by adding 1 µg/ml 4’, 
6-diamino-2-phenylindole [DAPI]  to the incubation medium. Sections were analyzed 
by comparing: (a) the localization of the fluorescence of FITC (activity) with that of 
rhodamine red (antigen); (b) the fluorescence of FITC formed after incubation in the 
presence of the DQ substrate with that produced after incubation in the absence of 
DQ substrate or in the presence of the DQ substrate and MMP inhibitors.  
In murine lung immunohistochemical detection of macrophages in 10µm cryosection 
slides was performed with a fluorescent detection method according to the 
manufacturer’s recommendations. Macrophages were detected with purified rat anti-
mouse Mac-3 monoclonal antibody and with rhodamine RedTM-X-conjugated 
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3.16 Data analysis 
Data are expressed as the mean ± SEM. Statistical analyses were performed with 
Graphpad Prism 4.02 software. Means between two groups were compared with 2-
tailed unpaired Student’s T-test, Wilcoxon test and 2-way ANOVA.  Furthermore, 
statistical comparisons between IPF and normal groups were performed using the 

















RESULTS               4.1.1 Histological phenotype of patient lungs 
 




4.1 IPF patient lungs manifest the typical UIP histological pattern with 
marked collagen deposition in the matrix. 
As a prerequisite of our study the histological phenotype of our patient population 
was examined. 
 
4.1.1 Histological phenotype of patient lungs 
A well known histological hallmark of IPF is the presence of fibroblastic foci in areas 
of active tissue remodelling adjacent to areas of normal tissue architecture225. We 
showed by haematoxylin and eosin staining of lung sections the typical UIP 
histological pattern in our patient study population (Figure 7b, 7e).  
 
Masson trichrome stain showed deposition of collagen and other matrix proteins in 
the pulmonary interstitium of IPF patients compared to control lungs (Figure 7d, 7f 
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 Figure 7: IPF lungs show the typical histological pattern of usual interstitial 
pneumonia and increased collagen deposition. 
Paraffin sections from control and IPF lungs were stained with routine stains for 
histological assessment. Shown are representative lung sections from a control 
lung (a, c) and an IPF lung (b, d, e, f) stained with either haematoxylin & eosin (a, 
b, e) for general histological assessment and Masson trichrome for collagen and 
other matrix proteins (c, d, f).  a & c,10X objective , scale = 100µm;  
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 4.1.2 Hydroxyproline levels are increased in IPF  lungs 
Collagen deposition in IPF lung parenchyma was quantified by determining the 
hydroxyproline content (Figure 8) of lung tissues. Compared to control lungs we 
observed a moderate increase in lung hydroxyproline in two out of three different 
peripheral regions of the same lobe.The highest hydroxyproline content was 










   
 Figure 8:  Hydroxyproline content of control and IPF patient lung tissues. 
Lung tissue was taken from 3 different regions from the basal part of IPF lungs 
(n=8) and analysed for collagen deposition as described in the methods. Given 
are the hydroxyproline content in µg/mg lung dry weight. Comparison to control 
lung (n=6) was undertaken. Data are from three independent experiments and 
are presented as scatter dot-plot wherein the horizontal line within each group 
represents the mean hydroxyproline value. 
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4.2  Expression of MMPs and TIMPs in IPF and control lungs 
The expression of MMPs and TIMPs at the transcriptional level was analyzed in 
homogenates from IPF and donor lungs and commercially available normal lung 
preparations (see Table 2 in Methods). In addition, MMP and TIMP protein 
expression was analyzed in IPF and donor lung homogenates and MMP-13 protein 
was localized in lung tissue. Furthermore, collagenolytic and gelatinolytic activities 
were analyzed.  
 
4.2.1 mRNA expression of collagenases and matrilysin are upregulated 
in IPF lungs compared to control lungs 
We first investigated MMP and TIMP expression at the mRNA level in IPF and 
control lungs by quantitative real time PCR. As compared to control lungs, mRNA 
expression of the collagenases MMP-1 and MMP-13 mRNA was greatly increased 
(44.8 fold and 57.1 fold, respectively). In addition, MMP-7 mRNA expression in the 
lungs of IPF patients was upregulated 11.8 fold (Figure 9). Expression of MMP -2, -
8, -9, -12 and -14 was not significantly different between IPF and donor lungs. 
Among the TIMPs, only TIMP-4 was found to be significantly altered at the mRNA 
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 Figure 9:  mRNA expression in control lungs and IPF patients. 
Total RNA from control (n =7) and IPF patients (n =14) was reversed transcribed 
as described in the methods. mRNA transcripts of MMPs and TIMPs were 
quantified by quantitative RT-PCR and normalized as a ratio to human  ß-actin 
as housekeeping gene. Data presented is the average quantification of 2 
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 4.2.2 Increased protein content of MMP-1,-2, -7, -9, -13  in IPF lungs 
compared to controls  
We employed western blot analysis to determine the expression of MMPs and 
TIMPs at the protein level. After densitometric analysis of the protein band intensities 
(Figure 10a), significant upregulation of protein in IPF versus control lungs was 
observed for MMP-1 (~2 fold), MMP-2 (~2 fold), MMP-7 (5.5), MMP-9 (~2 fold) and 
MMP-13 (~2 fold). In contrast, MMP-8 protein levels were reduced in IPF. None of 
the TIMPs showed significantly different expression at the protein level. We became 
interested in MMP-13 because among the MMPs analyzed the mRNA was 
increased the most. However, there was a lower level of protein than was 
anticipated from the mRNA expression data. We then examined the protein 
expression utilizing antibodies specific for the pro-and active form of MMP-13. We 
clearly demonstrated a high abundance of active MMP-13 protein in the IPF versus 
donor lungs (Figure 10b). To further corroborate these data and to identify the 
cellular source of MMP-13, immunohistochemistry was performed. Weak MMP-13 
immunoreactivity was detected in the normal lung tissue (Figure 10c). However, in 
the lungs of IPF patients immunoreactive MMP-13 was easily detected in 
macrophages, in the alveolar and bronchiolar epithelial cells, alveolar septae and in 
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 Figure 10: MMP-13 protein expression is upregulated in IPF lungs  
 (a) Protein expression of MMPs and TIMPs were analyzed by Western blot and 
data are shown as the normalized integrated density value (IDV) to that of actin as 
loading control. Data presented are from three independent experiments. *p< 0.05 and ** 
p<0.001 compared to control. (b) Representative Western blot demonstrating increased 
protein expression of both the latent and active form of MMP-13 in IPF versus control.(c) 
Only weak MMP-13 immunoreactivity was observed in the control lungs, 10x objective, 
scale = 100µm. (d) MMP-13 immunohistochemistry confirms increased MMP-13 
expression in IPF lungs. MMP-13 localized mainly to alveolar, bronchiolar epithelia cells 
(arrow), and alveolar macrophages; 10x objective, scale = 100µm. (e) Higher power 
view of showing abundant MMP-13 immunoreactivity (arrows); 20X objective, scale 
=50µm. 
 
4.2.3 Increased collagenase and gelatinase activity in IPF versus 
control lungs 
We further investigated if the increased protein levels of the collagenases and 
gelatinases would result in an increased activity. Collagenase activity in lung 
homogenates was measured by a fluorescence substrate assay and gelatinase 
activity was assessed by gelatin substrate zymography. Increased collagenase 
activity was observed in IPF compared to control lungs (Figure 11a). However, due 
to the limited number of samples investigated, this change did not reach statistical 
significance. We observed no difference in MMP-9 activity between IPF and control 
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lungs, but MMP-2 activity was significantly increased in IPF as compared to controls 
(Figures 11b, 11c and 11d). Development of lytic zones could  
be fully inhibited  in control gels which were incubated in the presence of EDTA 
(data not shown). 
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     Figure 11: Increased collagenase and gelatinase activity in IPF versus control   
lungs. 
(a) Microtiter plate based fluorescent substrate assay for collagenase activity in control 
(n=6) and IPF (n=8) lungs. Shown is a scatter-dot plot representing data  
from three independent experiments, wherein the horizontal line within each group 
represents the mean value. (b) Representative zymogram of gelatin substrate 
zymography of homogenates of control and IPF lungs; lytic zones of MMP-2 and MMP-9 
activity appear white over the dark background. Densitometric analysis of pro- and 
active-MMP-2 activity (c); and of pro- and active MMP-9 activity (d). **p < 0.01 IPF 
compared to controls. 
 
 
4.2.4 Spatial distribution of MMP antigen signal and collagenolytic and 
gelatinolytic activity in IPF and controls 
In order to better judge on the spatial distribution of MMP protein signal and activity 
and in face of overlapping substrate specificities118, 120, we employed collagen in situ 
zymography (ISZ) alongside with MMP-1 and -13 immunohistochemistry in order to 
correlate MMP-1 and -13 with collagenase activity. In addition, gelatin in situ 
zymography was performed simultaneously with MMP-2 immunohistochemistry in 
order to correlate MMP-2 with gelatinase activity. Whereas minimal activity and 
protein expression were observed in control lung tissue (Figure 12), we observed 
abundant MMP-1 and MMP-13 protein staining and partial co-localization with 
collagenase activity in alveolar epithelial cells lining fibroblastic foci and areas of 
dense fibrosis. We also found that MMP-2 protein and gelatinolytic activity co-
localized in the endothelial and interstitial spaces of IPF lungs, but was not present 
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in the control lungs, thus underscoring the contribution of MMP-2 to the matrix 
remodelling process. 
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 Figure 12:  In situ zymography of MMPs in IPF. 
Representative photomicrograph of in situ zymography combined with    
immunohistochemistry showing little collagenolytic activity and almost absence 
of MMP-1 (not shown) and MMP-13 protein signals in controlsl (a). In IPF 
tissues collagenolytic activity co-localized with MMP-13 (b), and MMP-1(c) in 
alveolar epithelial cells. Gelatinolytic activity co-localizes with MMP-2 (d).  
 (Blue=nuclei, red = MMP-13 in (a) and (b), MMP-1 in (c), and MMP-2 in (d); 
  green = collagenase activity (a, b, c) or gelatinase activity (d) 10X objective,  
 Scale = 100µm.  
 
4.3  Role of MMP-13 in the pathogenesis of fibrotic lung disease 
As a result of our studies, we identified MMP-1 and MMP-13 as key collagenases 
upregulated in human IPF.  Because rodents lack the orthologue of human MMP-1, 
we further investigated the relevance of the collagenase, MMP-13, in a murine 
model of bleomycin induced lung fibrosis. We examined the fibrotic response to 
bleomycin in MMP-13-/- and their in-bred wild type littermates.  
In addition, we analyzed MMP activity in BAL fluid and expression of collagenases 
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4.3.1 MMP-13-/- mice develop exaggerated inflammation following  
  bleomycin challenge. 
To characterize the bleomycin-induced inflammatory response in MMP-13-/- and wt 
littermates, we assessed total cell counts and cell differentials of cytospins from 
BALF at various time points after treatment (Figure 13a). Likewise to their littermate 
wt controls, MMP-13-/- mice showed a significantly elevated total cell count in 
response to bleomycin challenge which was caused largely by an influx of 
granulocytes and lymphocytes into the alveolar space of both mice. However, the 
extent of cell transmigration seemed to be much higher in the MMP-13-/- mice, 
reaching a significantly increased total cell count on d7 and d14 and a significantly 
increased relative number of neutrophils. Histological examination of lung sections 
from control MMP-13-/- and wt mice revealed an essentially normal lung architecture, 
with no differences between wt and MMP-13-/- mice (Figure 13b, 13e). 7d and 14d 
after bleomycin treatment, both, wt mice (Figure 13c and 13d, respectively) and 
MMP-13-/- mice (Figure 13f and 13g, respectively) developed patchy areas of 
inflammation throughout the lung parenchyma, with MMP-13-/- mice displaying a 
more severe and longer lasting inflammatory response to bleomycin. In accordance 
with the BALF findings, septal infiltration with lymphocytes and neutrophils was more 
prominent in MMP-13-/- as compared to wt mice, with some predominance in sub-
pleural and peribronchial areas.  
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Figure 13: Inflammatory changes in MMP-13-/- and wt mice after bleomycin 
  challenge  
Total cells and percentages of macrophages, neutrophils and lymphocytes  
were determined in BALF from wt  and MMP-13 -/- mice, 7 days after saline 
application (control) and 7d, 14d, and 28d  after bleomycin treatment (a). Results 
are presented as mean ± SEM, n = 4 - 5 per group. *p< 0.05 versus control,  
#p < 0.05 versus corresponding wt value. Histologic evaluation of lungs at 7 and 
14 days postbleomycin challenge in wt and MMP-13-/- mice. Representative lung  
sections from wt (b, c, d)  and  MMP-13-/- (e, f, g) mice were H&E-stained. 
Inserts in (c) and (d) and (f) and (g) show phenotypic changes as marked.  
      (Objective: a & b, x10; b, c, e, & f, x4; inserts, x20). Scale = 100µm.  
 
4.3.2 Regulation of chemotatic activity in macrophages from  
MMP-13-/- mice 
To better understand the sustained inflammatory reaction in MMP-13-/- versus wt 
mice in response to bleomycin, we performed a macrophage chemotaxis assay 
using BALF from MMP-13-/- and wt mice as the chemoattractant, and fluorescently 
labeled alveolar macrophages (AMJ2-C11 macrophage cell line) as responding 
cells. We noted that BALF from MMP-13-/- mice, obtained 7days after bleomycin 
challenge, exerted a slight, although significant, increase in chemoattraction to 
macrophages as compared to BALF from bleomycin or saline challenged wt mice 
(Figure 14). 
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 Figure 14:  Increased macrophage chemotaxis to BALF from bleomycin    
challenged MMP-13-/- versus wt mice  
 BALF was obtained from control and bleomycin treated and MMP-13-/-  
and wt mice (n = 3 per group). The alveolar macrophage cell line AMJ2-C11 was 
used as responding cells. Data are presented as mean ±  SEM, and are a 
representative of 2 independent experiments. * p< 0.05 comparing chemotaxis 
























RESULTS              4.3.3 MMP-13-/- mice show more extensive lung fibrosis 
 Regulation and pathomechanistic role of matrix metalloproteinases in idiopathic pulmonary fibrosis   92
4.3.3 MMP-13-/- mice show more extensive lung fibrosis in response to 
bleomycin administration. 
We then analyzed the lung collagen content and extent of lung fibrosis in bleomycin 
challenged MMP-13-/- and wt mice. Figure 15 shows representative Mason-
Trichrome-stained lung sections (3 slides per lung and 5 random microscopic fields 
per slide examined) from control and bleomycin challenged wt (a & b) and MMP-13-/- 
(c & d) mice at d28. As evident from this figure, MMP-13-/- mice showed more 
extensive lung fibrosis and collagen deposition as compared to WT mice. Similar 
results were already observed at d14 (data not shown).  
 
Analysis of lung hydroxyproline content (Figure 15e) revealed similar results: 
hydroxyproline levels were similar in control wt and MMP-13-/- mice in the absence of 
challenge, and challenge with bleomycin resulted in a significant increase in lung 
hydroxyproline content in wt and MMP-13-/- mice. However, hydroxyproline content 
of MMP-13-/- mice was significantly higher compared to the respective wt mice, 28d 
after bleomycin challenge. 
 
In line with this observation, the lung compliance (Figure 16) of bleomycin 
challenged MMP-13-/- mice on d28 were significantly decreased as compared to 
bleomycin challenged wt mice. 
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 Figure 15: Increased lung collagen content in MMP-13-/- versus wt mice in 
response to bleomycin treatment.  
 Representative lung sections from wt (a and b) and MMP-13-/- (c and d)  
mice stained with Masson-Trichrome stain for collagen and matrix proteins are 
given. (e) Hydroxyproline content in wt and MMP-13-/- lungs, control (saline) and 
at 7, 14 and 28d after bleomycin treatment, (n = 4-5 per group)  
 Data are representative of two experiments and presented as mean ± SEM.  











 Figure 16:  Lung compliance of control and d28 bleomycin treated 
               MMP-13-/- and wt mice.  
Lung compliance of mice (n = 3-5 per group) was measured as described in 
methods. Data are presented as mean compliance ± S.E.M, p value is indicated. 




















  P = 0.027
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 4.3.4 Expression of MMPs and TIMPs in MMP-13-/- and WT mice 
We next assessed the effect of bleomycin on the expression pattern of MMPs and 
TIMPs and to identify a potential compensation for the loss of MMP-13 in MMP-13-/- 
mice. As depicted in Figure 17a, MMP-7 mRNA was upregulated in wt and in MMP-
13-/-  mice in response to bleomycin challenge (d28), however, MMP-7 mRNA was 
not different in wt versus MMP-13-/- treated mice and this was also encountered in 
lung specimen from the other time points post bleomycin challenge (data not 
shown). Such observation was further corroborated by immunohistochemistry of 
lung sections obtained d28 after bleomycin challenge: in here, MMP-7 
immunostaining (Figure 17b) was absent in untreated lungs, but was found to be 
present in MMP-13-/- and wt mice (Figure 17b). In contrast, MMP-8 mRNA 
expression was found to be elevated in MMP-13-/- versus wt mice in absence of any 
challenge. In response to bleomycin challenge MMP-8 was induced in MMP-13-/- 
and wt mice, however, with much higher mRNA levels in the MMP-13-/- mice (Figure 
17c). As expected, MMP-13 transcripts were not observed in the MMP-13-/- mice, 
whereas MMP-13 was found to be greatly induced in response to bleomycin 
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 Figure 17:  Expression of Mmps-7, 8, 13 in lungs of wt and  
              MMP-13-/- mice in response to bleomycin challenge. 
Total lung RNA was obtained from saline treated (control, left bar) or bleomycin-
treated (right bar) mice at d28 and analyzed for mRNA transcripts of Mmp-7 (a), 
Mmp-8 (c),  Mmp-13 (d) using quantitative RT- PCR and normalized as a ratio to 
mouse ß-actin as housekeeping gene. Data are shown as mean ddCt ± SEM 
from 3-5 mice per treatment group. * p< 0.05, ** p< 0.001, ***p< 0.0001 
compared to wt control; # p< 0.05, # # p< 0.001, # # #p< 0.0001 compared to MMP-
13-/- control.(b) MMP-7 protein immunostaining in distal airways of wt (upper 
panel) versus MMP-13-/- (lower panel) mice. No MMP-7 staining was observed  

























 P = 0.2145


























RESULTS           4.3.4  Expression of MMPs and TIMPs in MMP-13-/- and WT mice  
 Regulation and pathomechanistic role of matrix metalloproteinases in idiopathic pulmonary fibrosis   98
We also analysed mRNA expression level of Timp-1 (Figure 18a), Timp-2 (Figure 
18b), Timp-3 (Figure 18c) and Timp-4 (Figure 18d) in the lungs of wt and MMP-13-/- 
mice, control and 28d after bleomycin treatment. We observed significantly elevated 
levels of these mRNAs in MMP-13-/- versus wt mice in absence of bleomycin 
challenge (Figure 18) and significant induction of these TIMPs in response to 
bleomycin challenge (Figure 18)        











Figure 18: mRNA expression of Timps in wt and MMP-13-/- mice 
mRNA expression of Timps-1 (a), -2 (b), -3 (c) and -4(d)  was analysed by quantitative RT-PCR in 
lung specimen of saline treated (control, left bars) and bleomycin challenged (d28, right bars) 
mice. Data are shown as mean ddct ± SEM from 3-5 mice per treatment group.  
* p< 0.05, ** p< 0.001, ***p< 0.0001 compared to wt control;  
























    P < 0.05
















































































   (c) 
(b) 
(d) 
DISCUSSION                   5.1 Role of MMPs and TIMPs in pulmonary diseases 
 Regulation and pathomechanistic role of matrix metalloproteinases in idiopathic pulmonary fibrosis   99
 
5. DISCUSSION 
5.1  Role of MMPs and TIMPs in Pulmonary Diseases 
MMPs have been implicated in various pathologies. Redundant diseases associated 
with MMP regulation include: aortic aneurysms226-229, atherosclerosis230-232, 
rheumatoid and osteoarthritis233, 234, nephritis235-238, tumor growth and migration239-
241,  and tissue ulcers118, 120, 242, 243. Dysregulation of MMP activity has been 
associated with lung diseases such as cancer, emphysema and fibrosis91, 117, 244-248.  
For this reason, MMPs have become an important focus for basic science studies 
and clinical investigations by lung biology researchers and are important players in 
the future diagnosis and treatment of lung disease involving excessive matrix 
remodelling. 
 
Almost all of the MMPs can be identified in lung tissue. In view of the predominant 
extracellular matrix (ECM) compounds of the lung, in particular type I and II collagen 
and elastin, the collagenases, gelatinases, matrilysin and macrophage 
metalloelastase are of major interest.  These MMPs are counterbalanced by the four 
TIMPs, among which TIMP 1 and 2 seem to play a major role in ILDs249. Under  
conditions of lung fibrosis a differential pattern of MMP and TIMP expression has 
been observed and suggested to contribute to the evolution of the disesase 250, 251. 
In IPF, MMP 9 expression was found to be elevated 252, whereas in COP or NSIP, 
MMP 2 expression seemed to be preferentially upregulated 253. The gelatinases 
(MMP-2 and -9)253-255 and neutrophil elastase (MMP-8)255 have been shown to be 
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elevated in the BALF and lungs of IPF patients. RNA and protein levels  of MMP-7 in 
particular, have been shown to be increased in both human and experimental lung 
fibrosis86. In addition to MMP-7, increased MMP-1 expression levels were recently 
found in BALF and plasma of IPF patients86, 256. 
 
Recently, epigenetic modifications have been shown to contribute to MMP regulation 
168. Studies  performed using transgenic or knock out mice also revealed the 
fundamental significance of  MMPs in the development of emphysema257,258 and lung 
fibrosis86.  As an example, MMP-1 overexpressing mice do develop emphysema in 
spite of normal elastin content 257. In parallel, increased collagenase (MMP-1) 
activity has been observed in BAL and lung parenchyma from emphysema  patients 
and could be localized to alveolar type II cells259. Furthermore, MMP-12 KO mice 
were shown to have a normal lung phenotype even after exposure to cigarette 
smoke 260,  and  in yet another study, MMP-12 KO mice were not protected from 
bleomycin-induced lung fibrosis90. MMP-7 KO mice were shown to be  protected 
from bleomycin-induced lung fibrosis86 and MMP-9 KO mice showed decreased 
alveolar bronchiolization after bleomycin-induced lung fibrosis89, thus underscoring  
the important contribution of single MMPs in the dynamic regulation of the ECM and 
of remodeling processes in  the lung91. 
MMP-13 (also known as collagenase-3) is the major interstitial collagenase of 
rodents and has a high specificity for degrading insoluble fibrillar collagens 
especially type II and I collagens 180, 261. The expression of  MMP-8 and -13 were 
shown to be down-regulated in a model of pulmonary fibrosis induced in rats with 
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paraquat and hyperoxia 251.  MMP-13 was recently shown to play a role in the 
pathogenesis of liver fibrosis 180 but its role has never been studied in murine models 
of lung fibrosis such as the bleomycin-induced lung fibrosis model.  
  
Less is known about the regulation of TIMPs under conditions of IPF. Under 
experimental conditions, it is observed that the concentration of TIMP-1 and TIMP -2 
proteins was elevated more than 200 fold in bleomycin induced lung fibrosis, 
suggesting an imbalance of MMP and TIMP. In addition, Selman and colleagues 
reported increased TIMPs 1, -2, -3 and -4 expression levels in the lungs of IPF 
patients compared to normal lungs82.  
 
Taken together, elevated levels of MMPs have been implicated in the 
pathophysiology of various lung diseases, including acute respiratory distress 
syndrome, asthma, bronchioectasis, and cystic fibrosis. MMPs, EMMPRIN257, 262, 
and TIMPs are produced by many of the resident cells in the lung, hence 
complicating the analysis of their role under disease conditions. Potential use of 
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 5.2  Regulation of MMP and TIMP expression and activity in human 
lungs. 
In the present study, the expression pattern of several MMPs and TIMPs was 
analyzed in explanted IPF versus normal and donor lungs and the spatial distribution 
of MMP-13 and MMP-2 antigen signal correlated with the collagenolytic and 
gelatinolytic activity as assessed employing in situ zymography. Among all MMPs 
and TIMPs studied in lung homogenates, only the collagenases MMP-1 and MMP-
13, and MMP-7 were found to be significantly upregulated on the mRNA and protein 
level and served as an explanation for the overall increased collagenolytic activity in 
IPF lung homogenates. Although the gelatinases MMP-2 and MMP-9 were 
unchanged on the mRNA level, a roughly 2 fold increase in these gelatinases was 
encountered at the protein level in IPF versus donor lung homogenates. Against our 
anticipation, TIMPs-1 - 4 were not found to be significantly increased in IPF 
homogenates, neither at the mRNA nor at the protein level. At a quick glance, this 
observation contrasts with the observed increase in hydroxyproline content, 
especially in the subpleural areas of IPF. Our data seem also not to support  the 
previous suggestion of a  far-reaching blockade of MMP activity by overwhelming 
TIMP levels82 as the underlying principle of increased ECM content in IPF. Despite 
our restriction to only study MMP-1, -2 and -13 on the level of in situ zymography 224 
and some theoretical limitations of assessing MMPs on the level of lung homogenate 
263, 264, the most reasonable explanation for our observation is, however, that either 
production and deposition of ECM  exceeds the capacity of the ECM degradation 
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machinery or that the spatial distribution of proteolytic activity is poorly distributed or 
both 265.  Indeed, our in situ zymography data do suggest that collagenolytic and 
gelatinolytic activities were not exclusively co-localizing with the respective MMP 
antigen signals in the lung tissues, suggesting free and overwhelming MMP activity 
within the airways and weaker activity in the scar regions. Such an observation may 
also serve as a potential explanation for the development of honeycomb cysts, an 
obviously inappropriate loss of lung architecture and puzzling feature of IPF and 
many other progressive forms of lung fibrosis 13, 14, 34, 266-268.  
 
 5.3  Upregulation of MMP-13 protein in human IPF lungs 
A prominent and novel finding is our observation of the upregulation of pro- and 
active MMP-13 protein in IPF lungs. In lung tissue of IPF patients MMP-13 protein 
was found to be localized in alveolar and bronchiolar epithelial cells, alveolar 
macrophages, the alveolar septae and areas of remodelled interstitial lung tissue. 
This was an interesting finding, as the group of Selman82 showed MMP-1, otherwise 
known as interstitial collagenase, to be localized in the bronchiolar epithelial cells but 
not in the interstitial space, where abundant extracellular matrix is found. Ortiz and 
colleagues269 previously demonstrated MMP-13 overexpression in lungs of silica-
treated TNF receptor-deficient mice and by in situ hybridization, showed that MMP-
13 mRNA hybridized to the cytoplasm of macrophages inside silicotic nodules.  
Therefore, our results suggest that MMP-13 might be playing an important role in the 
pathogenesis of IPF especially at the level of tissue repair and remodeling.  
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 5.4 Role of MMP-13 in pulmonary fibrosis 
MMP-13 is the major proteinase that shows substrate specificity towards interstitial 
fibrillar collagens I, II, III and gelatin, preferentially cleaving type II collagen179. Drawn 
against this background and as MMP-13 had been recently shown to play a 
significant role in bone remodeling defects in skeletal diseases179, 184,  to reduce liver 
fibrosis180, and to increase collagen accumulation in atherosclerotic plagues270, we 
hypothesized that MMP-13 might also play a role in pulmonary fibrosis. 
 
Employing the model of bleomycin induced lung fibrosis we investigated the role of 
MMP-13 in pulmonary fibrosis and firstly observed an exaggerated early 
inflammation in the MMP-13-/- mice. In detail, total BALF cell numbers of bleomycin 
challenged MMP-13-/- mice progressively and significantly increased during the first 
14 days as compared to challenged WT littermates and this was found to be due to 
an exaggerated neutrophilic response in the MMP-13-/- mice. Contrary to our 
findings, previous studies reported less neutrophil accumulation in MMP-9-/- mice89, 
and MMP-12-/-  mice 90, 271  after bleomycin treatment whereas in WT mice a 
remarkable infiltration of neutrophils and lymphocytes characterized the initial 
inflammatory response  to bleomycin. MMPs are known to proteolytically process 
chemokines and activate pro-inflammatory cytokines causing an increase in their 
chemotactic activity for inflammatory cells258, 272, 273. In spite of these known effects 
of MMPs, BALF from MMP-13-/- mice exerted a stronger chemoattraction toward 
macrophages. The underlying reason for the observed hyperinflammation in MMP-
13-/- mice is currently not clear and deserves further studies. However, an 
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explanation for our observation could be a putative role of MMP-13 in the proteolytic 
inactivation of pro-inflammatory cytokines or chemokines. 
 
Starting at d14 after bleomycin challenge, an augmented fibrotic response was 
encountered in the MMP-13-/- mice and it is currently unclear if this augmented 
fibrotic response was caused by the more extensive inflammation or the pure 
absence of MMP-13. This holds especially true when considering that MMP-7 was 
found to be similarly upregulated in both MMP-13-/- and wt mice, and the TIMPs 
were not dramatically altered in MMP-13-/- versus wt mice in response to bleomycin 
challenge. One intriguing interpretation of our experimental data would also be a 
compensatory, but insufficient upregulation of MMP-8 in order to substitute for 
missing MMP-13. Somewhat in line with such reasoning, Raulo and colleagues274 
had previously reported a positive correlation (in tracheal epithelial lining fluid [TELF] 
of horses) between immunoreactivity of MMP-8 and MMP-13 and the amount of 
degradation of type I collagen. Macrophages and epithelial cells were observed as 
the major cellular sources of MMP-8 and MMP-13 in the above study. Supporting the 
hypothesis of  reciprocal compensation of  MMP deficiency,  Lindsey and 
colleagues275 reported significantly lower levels of MMP-13 in the left ventricle of 
MMP-7-/- mice whereas pro-MMP-8 levels were elevated. Our data show increased 
fibrosis in MMP-13-/- mice in response to bleomycin, in contrast to MMP-7-/- mice that 
were shown to be protected from bleomycin-induced lung fibrosis86. Obviously, this 
differential and, indeed, opposite impact of knock out of single MMPs on the 
development of lung fibrosis indicates distinct roles of each MMP. Although purely 
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speculative at the present time, our observations alongside with unpublished data 
could suggest that MMP-13 and MMP-8 are regulated synergistically in fibrotic 
repair. However, further studies are required to define such a possible interaction. 
 
We observed no difference in MMP-2 and MMP-9 activities between bleomycin-
treated MMP-13-/- and wt mice. Since there was a robust increase in the BALF total 
cell count in MMP-13-/- versus wt mice, with a huge proportion of these cells being 
macrophages, it might be speculated that, following bleomycin administration MMP-
13-/- mice would have more gelatinase activity being released as the enzyme is 
secreted  into the alveolar lining layer. However, the lack of an increase in total 
gelatinolytic activity of the cell free BALF does not support such a concept. In 
addition, macrophages secrete the gelatinases into the alveolar lining layer but these 
enzymes may be diluted out at the time of lavaging and retrieving the BAL fluid from 
the lungs. Alternatively, a larger portion of the increase in the gelatinase post-
bleomycin could originate from the epithelial cells and therefore, the difference in 
macrophage gelatinase becomes undetectable. 
In summary, in an attempt to define the spatial expression and the nature of MMP 
activity in IPF, the contribution of TIMPs in the local inhibition of MMPs and the 
relative contribution of single MMPs in the process of fibrotic repair in IPF, we could 
show that  
(a) TIMPs are not excessively upregulated as compared to MMPs in IPF lungs; the 
collagenolytic activity of IPF tissue homogenates is higher as compared to donor 
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lungs, thus the increase in collagen deposition seems to be largely due to excessive 
matrix synthesis and deposition rather than blockade of MMPs;  
 
(b) collagenolytic and gelatinolytic activities do not colocalize completely with single 
MMP antigen signals in the lung tissues, suggesting a predominance of MMP activity 
within the airways and weaker activity in the scar regions (possibly providing one 
explanation for the process of honeycombing) and 
 
 (c) MMP-13 seems to play a significant role in IPF, as this collagenase is 
dramatically upregulated in lung tissue from IPF patients and as increased 
inflammation and excessive fibrosis are encountered in bleomycin challenged MMP-
13-/- versus control lungs.  
 
Our data therefore suggest that MMP-13 plays an important, (if not pivotal) role in 
the remodeling process in IPF, both in view of matrix deposition in the scarring 
areas, as well as in view of the development of honeycomb cysts, similar to the 
induction of emphysema formation in MMP-1 overexpressing mice257, 276. 
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6. SUMMARY 
Idiopathic pulmonary fibrosis (IPF) is a severe epithelial-fibroblastic disease with 
poor prognosis, characterised by excessive deposition of collagen in the pulmonary 
interstitium. Several matrix metalloproteinases (MMPs) and the tissue inhibitors of 
metalloproteinases (TIMPs) have been demonstrated to be strongly up-regulated in 
human and experimental lung fibrosis, thus underscoring their dynamic regulation of 
extracellular matrix and of remodeling processes in the lung. To investigate the 
spatial regulation, nature of MMP activity and the contribution of TIMPs in the local 
inhibition of MMPs in IPF, we examined IPF in comparison to donor lung tissue for 
regulation of MMPs and TIMPs, and the relative contribution of single MMPs to the 
fibrotic lung repair process.  
 
We identified MMP-7 and the collagenases, MMP-1 and -13, as key proteases 
upregulated in human IPF. A prominent and novel finding of our work is the 
upregulation of pro- and active MMP-13 protein in IPF patients. MMP-13 protein was 
localized in alveolar and bronchiolar epithelial cells, the alveolar septae and 
extracellular matrix of remodelled lung tissue. TIMP proteins were not differentially 
regulated; an observation that somehow contrasted with the increased 
hydroxyproline content, especially in the subpleural areas of IPF. We have shown by 
a combination of immunohistochemistry and in situ zymography that collagenolytic 
and gelatinolytic activities did not exclusively co-localize with a single MMP antigen 
signal in the lung tissues, suggesting predominant MMP activity within the airways 
and weaker activity in the scar regions.  
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Since mice lack the orthologue of human MMP-1, we investigated further the 
relevance of MMP-13 in the context of fibrotic lung diseases by examining the 
fibrogenic response to bleomycin in MMP-13-/- mice and wt littermates. In response 
to bleomycin challenge and likewise to their littermate wt controls, MMP-13-/- mice 
were characterized by elevated total cell counts in BALF caused largely by an influx 
of granulocytes and lymphocytes. Seven  and fourteen days after bleomycin 
treatment, both wt and MMP-13-/- mice developed patchy areas of inflammation 
throughout the lung parenchyma, with MMP-13-/- mice again displaying a more 
severe inflammatory response to bleomycin that  persisted for a longer time period. 
Likewise, the extent of fibrosis was more prominent in MMP-13-/- versus wt mice, 
with increased levels of hydroxyproline and more significant histologic signs of 
fibrosis. It is currently unclear if this augmented fibrotic response was caused by the 
more extensive inflammation or the absence of MMP-13, especially when 
considering that MMP-7 was found to be similarly upregulated in both MMP-13-/- and 
wt mice and the TIMPs were not dramatically altered in MMP-13-/- versus wt mice. 
 
In conclusion, in an attempt to define the spatial regulation and the nature of MMP 
activity in IPF, the contribution of TIMPs in the local inhibition of MMPs and the 
relative contribution of single MMPs in the process of fibrotic repair in IPF, we could 
show that (a) TIMPs are not excessively upregulated as compared to MMPs in IPF 
lungs; (b) the collagenolytic activity of IPF tissue homogenates is higher as 
compared to donor lungs, thus the increased collagen deposition seems to be 
largely due to excessive matrix synthesis and deposition rather than blockade of 
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MMPs, (c) collagenolytic and gelatinolytic activities do not colocalize completely with 
single MMP antigen signals in the lung tissues, suggesting the predominance of 
MMP activity within the airways and weaker activity in the scar regions (possibly 
providing one explanation for the process of honeycombing) and (d) MMP-13 seems 
to play a significant role in IPF, as this collagenase is dramatically upregulated in 
tissues from IPF patients and as excessive inflammation and fibrosis are 
encountered in bleomycin challenged MMP-13-/- mice versus control mice lungs.  
 
Our data therefore suggest that MMP-13 plays an important, (if not pivotal) role in 
the remodeling process in IPF, both in view of matrix deposition in the scarring 
areas, as well as in view of the development of honeycomb cysts, similar to the 
induction of emphysema formation in MMP-1 overexpressing mice. However, the 
mechanism of action of MMP-13 together with related mediators remains a subject 
for further investigation. 
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7.  ZUSAMMENFASSUNG 
Die Idiopathische Interstitielle Pneumonie (IPF) ist eine interstitielle 
Lungenerkrankung, der eine gestörte epitheliale-mesenchymale Interaktion 
zugrunde liegt, und die aufgrund eines rasch-progredienten und therapierefraktären 
Verlaufs eine äußerst schlechte Prognose aufweist. Ein Charakteristikum der IPF ist 
die exzessive Deposition von Komponenten der extrazellulären Matrix wie z.B. 
Kollagen. Für verschiedene Matrixmetalloproteinasen (MMPs) und deren Inhibitoren 
(tissue inhibitors of metalloproteinases, TIMPs) konnte eine differentielle Regulation 
bei der Lungenfibrose gezeigt werden, die auf eine dynamische Regulation des 
Stoffwechsels der Extrazellulärmatrix und auf kontinuierlich ablaufende 
Umbauprozesse in der Lunge hinweisen. Anhand von Lungengewebe von IPF 
Patienten wurde in der vorliegenden Arbeit die kompartimentalisierte Regulation der 
MMPs, die Quelle und Eigenschaften der MMP Aktikivät und die Beteiligung der 
TIMPs bei der IPF näher untersucht. Darüberhinaus wurde die relative Beteiligung 
einzelner MMPs am bei der Lungenfibrose gestörten Wundheilungsprozess 
untersucht.  
 
Wir konnten mit MMP-7 und den Kollagenasen MMP-1, MMMP-8 und MMP-13 
wichtige Schlüsselenzyme identifizieren, die bei der IPF heraufreguliert sind. Dabei 
konnte in der vorliegenden Arbeit erstmals die gesteigerte Expression von MMP-13 
(latentes und aktives Protein) im Lungengewebe von IPF Patienten gezeigt werden. 
MMP-13 wurde in alveolären und bronchiolären Epithelzellen, in Alveolarsepten und 
in der extrazellulären Matrix von bereits umgebautem Lungengewebe gefunden. Die 
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MMP Inhibitoren (TIMPs) hingegen zeigten keine differentielle Regulation, ein 
Befund, der im Widerspruch zu dem –vorallem in subpleuralen Gebieten der IPF 
Lunge- deutlich erhöhten Hydroxyprolin Gehalt steht. Mittels immunhistochemischer 
Verfahren in Kombination mit in situ Zymograhie konnte gezeigt werden, dass die 
gelatinolytischen und kollagenolytischen Aktivitäten nicht zwangweise mit einzelnen 
MMP Antigensignalen im Lungengewebe kolokalisiert waren; die prädominante 
MMP Aktivität wurde in den Atemwegen detektiert, in den fibrotischen Herden 
hingegen zeigte sich eine schwächere Aktivität.  
 
Da orthologe knockout Mäuse für humane MMP-1 nicht verfügbar waren, lag der 
weitere Focus auf der Untersuchung der Rolle von MMP-13 bei der 
Fibroseentwicklung am Modell der Bleomycin-induzierten Lungenfibrose unter 
Verwendung vom MMP-13 knockout Mäusen. Hinsichtlich der Zahl und der 
prozentualen Zusammensetzung lavagierbarer Zellen im alveolären Kompartiment. 
zeigte sich sowohl bei MMP-13-/- wie auch bei Wildtyp Mäusen ein Anstieg der 
Gesamtzellzahl, der auf einen Einstrom von Granulozyten und Lymphozyten in den 
Alveolarraum zurückzuführen war. An Tag 7 und Tag 14 nach Bleomycinapplikation 
war histologisch bei beiden Mäusen eine Entzündungsreaktion des 
Lungenparenchyms mit unregelmäßigem Verteilungsmuster festzustellen, das bei 
den MMP-13-/- Tieren jedoch stärker ausgeprägt war und über einen längeren 
Zeitraum bestand hatte. Dabei zeigten die Septen der Knockout Tiere eine stärkere 
Infiltration mit granulozytären und lymphozytären Zellen, mit einer Akzentuierung 
subpleuraler und peribronchiolärer Areale. Derzeit ist allerdings unklar inwieweit die 
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verstärkt ablaufende Fibroseantwort auf die gesteigerte Inflammationsreaktion oder 
das Fehlen von MMP-13 zurückzuführen ist, insbesondere wenn man berücksichtigt, 
dass MMP-7 sowohl in MMP-13 -/- wie auch Wildtyp-Mäusen heraufreguliert war und 
die TIMPs in MMP-13 -/- im Vergleich zu Wildtyp Tieren nicht substantiell verändert 
waren.  
 
Die wichtigsten Befunde dieser Arbeit lassen sich wie folgt zusammenfassen:  (a) im 
Gegensatz zu MMPs werden deren Inhibitoren (TIMPs) in Lungen von IPF Patienten 
nicht überhöht exprimiert. (b) die kollagenolytische Aktivität im Homogenat von IPF 
Lungen ist höher als in Homogenaten von Donorlungen. Die erhöhte 
Kollagendeposition scheint daher eher durch eine überhöhte Synthese von 
Komponenten der extrazellulären Matrix als durch die Inhibition der Degradation 
(MMP Inhibition) zustande zukommen. (c) die kollagenolytischen und 
gelatinolytischen Aktivitäten sind nicht zwingend mit dem Antigensignal einzelner 
MMPs co-lokalisiert, was eine Prädominanz der MMP Aktivität in den Atemwegen 
und eine geringere Aktivität in den fibrotischen Arealen vermuten lässt, und somit 
eine mögliche Erklärung für den Umbau zur Honigwabenlunge (honeycombing) 
liefert. (d) die erhebliche Überexpression von MMP-13 in IPF Lungen und die 
gesteigerte Fibroseantwort bei MMP-13 knockout Mäusen nach Bleomycin 
Schädigung legt nahe, dass diese Kollagenase eine wichtige Rolle bei der 
Fibroseentwicklung spielt. Die hier gezeigten Daten belegen, dass MMP-13 eine 
wichtige, wenn nicht sogar eine Schlüsselrolle bei den Umbauprozessen im Rahmen 
einer IPF einnimmt, und zwar sowohl was die Deposition von Extrazellulärmatrix in 
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den Fibroseherden betrifft, wie auch im Hinblick auf die Bildung der Honigwaben 
Zysten (analog zur Induktion der Emphysembildung bei MMP-1 überexprimierenden 
Mäusen). Zur Aufklärung der Mechanismen, über die die MMP-13 Effekte vermittelt 
werden, sowie zur Identifizierung der beteiligten Mediatoren müssen weiterführende 
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8. ABBREVIATION 
 
AECsII Type II Aveolar epithelial cells 
ANOVA Analysis of variance 
ARDS Adult respiratory distress syndrome 
BALF Bronchoalveolar lavage fluid 
BCA Bicinchoninic acid 
BOOP Bronchiolitis obliterating organizing pneumonia 
BSA Bovine serum albumin 
CaCl2 Calcium chloride 
cDNA Complementary deoxyribonucleic acid 
COMP Cartilage oligomeric matrix protein 
COPD Chronic obstructive pulmonary disease 
DAPI 4’, 6-diamino-2-phenylindole 
DPLD Diffuse parenchymal lung disease 
DQ Dye-quenched 
ECL Enhanced Chemiluminescence 
ECM  Extracellular matrix 
EDTA Ethylene diamine tetra-acetic acid 
ELISA Enzyme-linked immunosorbent assay 
EMMPRIN Extracellular matrix metalloproteinase inducer 
Ex/Em Excitation/Emission 
FITC Fluorescein isothiocyanate 
          ABBREVIATIONS 
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FN Fibronectin 
GPI Glycosylphosphatidyl inositol 
H & E Haematoxylin and eosin stain 
HP  Hypersensitivity pneumonitis 
HPS Hermansky-Pudlack Syndrome 
HRCT High resolution computed tomography 
IDV  Integrated density value 
IgG  Immunoglobulin 
IGFBP-3 Insulin growth factor binding protein-3 
IHC Immunohistochemistry 
IIP Idiopathic interstitial pneumonitis 
IL1-β Interleukin 1-beta 
ILD Interstitial lung disease 
IPAH  Idiopathic pulmonary arterial hypertension 
IPF Idiopathic pulmonary fibrosis 
ISZ In situ zymography 
kDa Kilo Dalton 
KO  Knockout 
MCP-3 Monocyte chemoattractant protein-3 
MgCl2 Magnesium chloride 
MMPs  Matrix metalloproteinases 
mRNA  Messenger ribonucleic acid 
MWM Molecular weight marker 
          ABBREVIATIONS 
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MT-MMP Membrane type- matrix metalloproteinase 
NaCl Sodium chloride 
NO  Nitric oxide 
NSIP Non-specific interstitial pneumonia 
PAH  Pulmonary arterial hypertension 
PAI -1 Plasminogen activator inhibitor-1 
PBS Phosphate buffered saine 
PDGF  Platelet derived growth factor 
PH  Pulmonary hypertension 
ROS  Reactive oxygen species 
RT-PCR  Reverse Transcription- Polymerase chain reaction 
RV  Right ventricle 
SDS-PAGE Sodium dodecyl-sulphate - polyacrylamide gel electrophoresis 
SEM  Standard error mean 
SMC  Smooth muscle cell 
SPARC Secreted protein acidic and rich in cysteine 
SP-C Surfactant protein-C 
TBS Tris buffered saline 
TBS/T Tris buffered saline containing Tween-20 
TELF Tracheal epithelial lining fluid 
TGF-β  Transforming growth factor-beta 
TIMPs Tissue inhibitors of metalloproteinases 
TM Transmembrane 
          ABBREVIATIONS 
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TNF-α Tissue necrosis factor-alpha 
t-PA  Tissue-type plasminogen activator 
UIP Usual interstitial pneumonia 
u-PA Urokinase-type plasminogen activator 
uPAR Urokinase-type plasminogen activator receptor 
VATS Video-assisted thoracoscopic surgery 
VEGF Vascular endothelial growth factor 
VN Vitronectin 
W.H.O  World Health Organization 
WT  Wild type 
ZnCl2 Zinc chloride
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